

GenCore version 5.1.3
Copyright (c) 1993 - 2002 Compugen Ltd.

OM protein - nucleic search, using frame_plus_p2n model

Run on: October 9, 2002, 17:55:09 ; Search time 230 Seconds
(without alignments)
6009.201 Million cell updates/sec

Title: US-09-635-501-2

Perfect score: 4291
Sequence: 1 MSSSSWLLSLVAVTAAGST.....ISRGNNPGFQNTDDVDTSF 805

Scoring table:
BLOSUM62
Xgapop 10.0 , Xgapext 0.5
Ygapop 10.0 , Ygapext 0.5
Fgapop 6.0 , Fgapext 7.0
Delop 6.0 , Delext 7.0

Searched: 1736436 seqs, 858457221 residues

Total number of hits satisfying chosen parameters: 3472872

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Command line parameters:
-MODEL=framet_p2n_model -DEV=xlh
-O=Cygn2_1/USPTO.spool/US09635501/runat_09102002_094528_18514/app_query.fasta_1.967
-DB=NGeneSeq_032802 -QFMT=fastp -SUFFIX=ring -MINMATCH=0.1 -LOOPCL=0
-LOOPEXT=0 -UNITS=bits -START=1 -END=1 -MATRIX=BIOSUM62 -TRANS=human40.cdi
-LIST=45 -DOCALIGN=200 -THR_SCORE=pct -THR_MAX=100 -THR_MIN=0 -ALIGN=15
-MODE=LOCAL -OUTFMT=ptc -NORM=ext -HEAPSIZE=500 -MINLEN=0 -MAXLEN=2000000000
-USER=US09635501 @CGN_1.1.7 @runat_09102002_094528_18514 -NCPU=6 -ICPU=3
-NO_XLPXY -NO_MMAP -LARGEQUERY -NEG_SCORES=0 -WAIT -LONGLOG -DEV_TIMEOUT=120
-WARN_TIMEOUT=30 -THREADS=1 -XGAPOP=10 -XGAPEXT=0.5 -FGAPOPOP=6 -FGAPEXT=7
-YGAPOP=10 -YGAPEXT=0.5 -DELOP=6 -DELEXT=7

Database : N_GeneSeq_032802.*
1: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1980.DAT.*
2: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1981.DAT.*
3: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1982.DAT.*
4: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1983.DAT.*
5: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1984.DAT.*
6: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1985.DAT.*
7: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1986.DAT.*
8: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1987.DAT.*
9: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1988.DAT.*
10: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1989.DAT.*
11: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1990.DAT.*
12: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1991.DAT.*
13: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1992.DAT.*
14: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1993.DAT.*
15: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1994.DAT.*
16: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1995.DAT.*
17: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1996.DAT.*
18: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1997.DAT.*
19: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1998.DAT.*
20: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA1999.DAT.*
21: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA2000.DAT.*
22: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA2001A.DAT.*
23: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA2001B.DAT.*
24: /SIDSI/gcgdata/hold-geneseq/geneseq-emb1/NA2002.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Match	Length	DB	ID	Description
1	4291	100.0	2418	21	AAZ59465	Human MPROT15 codi
2	4291	100.0	3334	22	AAC84366	Human face2 protei
3	4291	100.0	3396	21	AAAL2764	cDNA encoding a hu
4	4291	100.0	3396	22	AAD02758	Human angiotensin
5	4142	96.5	3732	22	AAS21279	Human cDNA sequenc
6	4061	94.6	2920	22	RAA14880	Human cDNA encodin
7	4013	93.5	2911	22	AAAS14890	Human MPROT15 codi
8	3740.5	87.2	2262	21	AAZ59466	Mouse face2-5 prot
9	3579	83.4	2638	22	AAC84368	Mouse face2-10 pro
10	3561	83.0	2638	22	AAC84370	Human face2 protei
11	3509	81.8	2415	22	AAC84367	Human cDNA encodin
12	3119	72.7	3474	22	AAAS2515	Mouse face2-5 prot
13	2899	67.6	2415	22	AAC84369	Encodes human test
14	1344	31.3	2477	12	AAQ10328	Human angiotensin-
15	1337	31.2	4020	21	AAAS38330	Human angiotensin
16	1337	31.2	4024	11	AAQ04027	Human angiotensin
17	1337	31.2	4024	20	AAAS38580	Human angiotensin
18	1336	31.1	4020	19	AAV41320	Human angiotensin
19	1334	31.1	3939	22	AAAS06085	Angiotensin conver
20	1334	31.1	4563	22	AAAS06057	Angiotensin conver
21	1310	30.5	3942	20	AAAS35851	Rat angiotensin co
22	1275	29.7	5005	22	AAH57430	Human intestine ce
23	1086	25.3	2089	23	ABL14379	Drosophila melanog
24	1057	24.6	2074	16	AAQ82948	Tick carboxypeptid
25	1028	24.0	2450	23	ABL16697	Drosophila melanog
26	961	22.4	9006	22	AAH77873	Nucleotide sequenc
27	941.5	21.9	5632	23	ABL14378	Drosophila melanog
28	919.5	21.4	5060	23	ABL16696	Drosophila melanog
29	721	16.8	2082	21	AAAS4692	Degenerate sequenc
30	721	16.8	2082	22	AAAS1469	Human zinc metallo
31	715.5	16.7	1395	22	AAH77876	Nucleotide sequenc
32	502.5	11.7	2025	23	ABL04671	Drosophila melanog
33	478	11.1	313	20	AAV86528	EST clone AU47. H
34	476	11.1	1836	23	ABL27143	Drosophila melanog
35	469	10.9	467	19	AAV09277	Nucleotide sequenc
36	445	10.4	5116	23	ABL04670	Drosophila melanog
37	444	10.3	4001	23	ABL27142	Drosophila melanog
38	414.5	9.7	2046	23	ABL05359	Drosophila melanog
39	387	9.0	666	22	AAF94460	Human hydrophobic
40	387	9.0	1347	22	AAF94470	Human hydrophobic
41	384	8.9	1401	19	AAV40540	Homo sapiens secre
42	383	8.9	847	20	AAAS30083	Human secreted pro
43	381	8.9	848	20	AAZ40770	Secreted protein e
44	381	8.9	848	20	AAAS88191	Human secreted pro
45	381	8.9	848	20	AAAS97564	Extended human sec

ALIGNMENTS

RESULT 1
ID AAZ59465 standard; DNA; 2418 BP.
AC AAZ59465;
XX
XX
XX 11-APR-2000 (first entry)
XX Human MPROT15 coding sequence #1.
XX

XX MPROT15; treatment; hypertension; human; myocardial disease; apoplexy;
XX heart disease; apoplexy; heart disease; nervous denaturation; ds;
XX Alzheimer's disease; hormone; cytokine.
XX

OS Homo sapiens.

XX JP11318472-A.

XX

PD 24-NOV-1999.
XX 22-JAN-1999; 99JP-0014949.
XX 13-MAY-1998; 98GB-0010373.
PR 18-AUG-1998; 98GB-0018009.
XX (SMK) SMITHKLINE BEECHAM PLC.
XX WPI; 2000-109268/10.
DR P-PSDB; AAY67310.
XX MPROT15 polypeptide and MPROT15 polynucleotides - useful for the
PT treatment of hypertension, myocardial diseases, apoplexy, heart
PT diseases, nervous denaturation, Alzheimer's disease etc.
XX Claim 7; Page 14; 22pp; Japanese.
XX This is the coding sequence of human MPROT15. The MPROT15 polynucleotide
CC and polypeptide sequences can be used for the treatment of hypertension,
CC myocardial diseases, apoplexy, heart diseases, nervous denaturation,
CC Alzheimer's disease and diseases related to the processing of peptide
CC hormones and cytokines.
XX Sequence 2418 BP; 744 A; 484 C; 555 G; 635 T; 0 other;
SQ
Alignment Scores:
Pred. No.: 0 Length: 2418
Score: 4291.00 Matches: 805
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 21 Gaps: 0
US-09-635-501-2 (1-805) x AA259465 (1-2418)
QY 1 MetSerSerSerSerTrrpLeuLeuSerLeuValAlaValThrAlaAlaGlnSerThr 20
DB 1 ATGCAAGCTCTTCCTGGCTCTCTCAGCCTGTGTGTAACTGCTGCATCCACCC 60
QY 21 IleGluGluGlnAlaLysThrPheLeuAspLysPheAsnHisGluAlaGluAspLeuPhe 40
DB 61 ATTGAGGAACAGCCAGACATTTTGGACAAATTTTAAACCAGGAAGCGACCTGTC 120
QY 41 TyrGlnSerSerLeuAlaSerTrpAsnTyrAsnThrAsnIleThrGluGluAsnValGln 60
DB 121 TATCAAGTTTCACCTGCTCTTGGAAATTAACCAATATTACTGAAGAAATGTCCAA 180
QY 61 AsnMetAsnAlaGlyAspLysTrpSerAlaPheLeuLysGluGlnSerThrLeuAla 80
DB 181 AACATGAATAATGCTGGGACAAATGGTCTGCTTTTAAAGGAACAGCTCCACACTTGC 240
QY 81 GlnMetTyrProLeuGlnGluIleGlnAsnLeuThrValLysLeuGlnAlaLeu 100
DB 241 CAATGATCCACTACCAAGAAATTCAGATCTCAGAGTCAAGCTTCAGCTGACGGCTTT 300
QY 101 GlnGlnAsnGlySerSerValLeuSerGluAspLysSerLysArgLeuAsnThrIleLeu 120
DB 301 CAGCAAAATSGGTCTTCAGTGCTCTCAGAAGACAAAGAGCAAGGTTGAACACAATTTCTA 360
QY 121 AsnThrMetSerThrIleTyrSerThrGlyLysValCysAsnProAspAsnProGlnGlu 140
DB 361 AATCAATGAGCACCATCTACAGTACTGGAAAGTTTGTAAACCCAGATAATCCACAAGAA 420
QY 141 CysLeuLeuLeuGluProGlyLeuAsnGluIleMetAlaAsnSerLeuAspTyrAsnGlu 160
DB 421 TGCTTATTAATGAACAGGTTTGAATGAATTAATGGCAACAGTTTACACTACATGAG 480
QY 161 ArgLeuTrpAlaTrpGluSerTrpArgSerGluValGlyLysGlnLeuArgProLeuTyr 180
DB 481 AGGCTCTGGGCTGGGAAGCTGGAGATCTGAGGTGGCAAGCAGCTGAGGCCATTATAT 540
QY 181 GluGluTyrValValLeuLysAsnGluMetAlaArgAlaAsnHisTyrGluAspTyrGly 200
DB 541 GAAAGATATGGTCTTGAATAATGAGATGGCAAGCAAAATCATTATGAGACTATGGG 600
QY 201 AspTyrTrpArgGlyAspTyrGluValAsnGlyValAspGlyTyrAspTyrSerArgGly 220
DB 601 CATTATTGGAGAGGAGACTATGAAGTAAATGGGTAGATGGCTATGACTACAGCGCGGC 660
QY 221 GlnLeuIleGluAspValGluHisThrPheGluGluIleLysProLeuTyrGluHisLeu 240
DB 661 CAGTTGATTGAAGATGTGAACATACCTTTTGAAGAGATTAACACCATTTATGAACATCTT 720
QY 241 HisAlaTyrValArgAlaLysLeuMetAsnAlaTyrProSerTyrIleSerProIleGly 260
DB 721 CATGCCATGTGAGGCAAAATGATGATGCTATCTCTCTATATCAGTCAATCGA 780
QY 261 CysLeuProAlaHisLeuLeuGlyAspMetTrpGlyArgPheTrpThrAsnLeuTyrSer 280
DB 781 TGCCTCCCTGCTCATTTGCTTGGTGTATGTGGGTAGATTTTGGACAAATCTGTACTCT 840
QY 281 LeuThrValProPheGlyGlnLysProAsnIleAspValThrAspAlaMetValAspGln 300
DB 841 TTGACAGTTCCCTTTGGACAGAAACCAACATAGATGTTTACTGATGCAATGGTGGACCG 900
QY 301 AlaTrpAspAlaGlnArgIlePheLysGluAlaGluLysPhePheValSerValGlyLeu 320
DB 901 GCCTGGGATGCACAGAGATATTCAAGAGAGCGCGAGAGTTCTTGTATCTGTGTGCTT 960
QY 321 ProAsnMetThrGlnGlyPheTrpGluAsnSerMetLeuThrAspProGlyAsnValGln 340
DB 961 CCTAATATGACTCAAGGATTTCTGGGAAATTCATGCTAACGACCCAGGAATGTTGTCAG 1020
QY 341 LysAlaValCysHisProThrAlaTrpAspLeuGlyLysGlyAspPheArgIleLeuMet 360
DB 1021 AAAGCAGTCTCCATCCACAGCTTGGGACTTGGGAGAGGCGACTTCAGGATCTTATG 1080
QY 361 CysThrLysValThrMetAspAspPheLeuThrAlaHisHisGluMetGlyHisIleGln 380
DB 1081 TGCAAAAGGTGACATGGAGACTTCTTCGACAGCTCATCATGATGGGCAATATCCAG 1140
QY 381 TyrAspMetAlaTyrAlaLagInProPheLeuLeuArgAsnGlyAlaAsnGluGlyPhe 400
DB 1141 TATGATATGGCATATGCTGCACAACTTTTCTGCTAAGAAATGGAGCTTAATCAAGGATTC 1200
QY 401 HisGluAlaValGlyGluIleMetSerLeuSerAlaAlaThrProLysHisLeuLysSer 420
DB 1201 CATGAGCTGTGGGGAATTCATGCTACTTTCGACGCCACACCTTACGATTTAAATCC 1260
QY 421 IleGlyLeuLeuSerProAspPheGlnGluAspAsnGluThrGluIleAsnPheLeuLeu 440
DB 1261 ATTTGCTCTTCTGTCACCGGATTTTCAAGAAGACAAATGAACACAGAAATAAAGCTTCT 1320
QY 441 LysGlnAlaLeuThrIleValGlyThrLeuProPheThrTyrMetLeuGluLysTrpArg 460
DB 1321 AAACAGCACTCAGCATTTGGGACTCTGCCATTTACTTACATGTTAGAGAAAGTGGAGG 1380
QY 461 TrpMetValPheLysGlyGluIleProLysAspGlnTrpMetLysLysTrpTrpGluMet 480
DB 1381 TGGATGGTCTTTAAAGGGGAATTTCCAAAGACCACTGGATGAAAGTGGTGGAGATG 1440
QY 481 LysArgGluIleValGlyValValGluProValProHisAspGluThrTyrCysAspPro 500
DB 1441 AAGCAGAGATAGTGGGGTGGGAACTGTGCCCATGATGAACACATCTGTGACCCC 1500
QY 501 AlaSerLeuPheHisValSerAsnAspTyrSerPheIleArgTyrTyrThrArgThrLeu 520
DB 1501 GCATCTCTGTTCATGTTTCTAATGATTAATCTCATTCATTCGATATTACAAAGACCTT 1560
QY 521 TyrGlnPheGlnPheGlnGluAlaLeuCysGlnAlaIleLysHisGluGlyProLeuHis 540
DB 1561 TACCAATTCAGATTTCAAGAGGACCTTTGTCAAGCAGCTTAAACATGAAGGCCCTCTGCAC 1620
QY 541 LysCysAspIleSerAsnSerThrGluAlaGlyGlnLysLeuPheAsnMetLeuArgLeu 560

Db 1621 AAATGTGACATCTCAAACTCTACAGAAGCTGGACAGAACTGTTCAATATGCTGAGGCTT 1680
QY 561 GlyLysSerGluProThrLeuAlaLeuGluAsnValValGlyAlaLysAsnMetAsn 580
Db 1581 GGAATATCAGAACCTTGGACCTAGCATTTGAAATGTTGAGGAGCAAGAACATGAAT 1740
QY 581 ValArgProLeuLeuAsnTyrPheGluProLeuPheThrTrpLeuLysAspGlnAsnLys 600
Db 1741 GTAAGGCCACTGCTCAACTACTTTTACGACCTTATTTACCTGGCTGAAAGACCAAGCAAG 1800
QY 601 AsnSerPheValGlyTrpSerThrAspTrpSerProTyrAlaAspGlnSerIleLysVal 620
Db 1801 AATCTTTTGGGATGGAGTACCAGCTGGAGTCCATATGAGACCAAGCAAGCAAGT 1860
QY 621 ArgIleSerLeuLysSerAlaLeuGlyAspLysAlaTyrGluTrpAsnAspAsnGluMet 640
Db 1861 AGGATAAGCTAAATCAGCTCTTGGAGATAAAGCATATGAATGAAAGCAAGCAAGT 1920
QY 641 TyrLeuPheArgSerSerValAlaTyrAlaMetArgGlnTyrPheLeuLysValLysAsn 660
Db 1921 TACTGTTCGATCATCTCTGATATGCTATGAGGAGTACTTTTAAAGTAAAGTAAAGT 1980
QY 661 GlnMetIleLeuPheGlyGluGluAspValArgValAlaAsnLeuLysProArgIleSer 680
Db 1981 CAGATGATCTTTTGGGAGGAGGAGTGTGGAGTGGCTAATTTGAAACCAAGATCTCC 2040
QY 681 PheAsnPhePheValThrAlaProLysAsnValSerAspIleIleProArgThrGluVal 700
Db 2041 TTTAATTTCTTGTCACTGCACCTTAAATGTCTGTATATCATCTAGAACCTGAAGTT 2100
QY 701 GluLysAlaIleArgMetSerArgSerArgIleAsnAspAlaPheArgLeuAsnAspAsn 720
Db 2101 GAAAGGCCATCAGGATGTCGCGAGCGGTATCAATGATGCTTTCCTGCTGAATGACAAC 2160
QY 721 SerLeuGluPheLeuGlyIleGlnProThrLeuGlyProProAsnGlnProProValSer 740
Db 2161 AGCTAGATTTCTGGGATACAGCCACACTTGGACCTCTACACGACCCCTGTTTCC 2220
QY 741 IleTrpLeuIleValPheGlyValValMetGlyValIleValIleValIleValLeu 760
Db 2221 ATATGGCTGATTTGTTTGGAGTTGTGATGGAGTGATAGTGGTGTGCTTGTCACTCTG 2280
QY 761 IlePheThrGlyIleArgAspArgLysLysLysAsnLysAlaArgSerGlyGluAsnPro 780
Db 2281 ATCTTCATGGATCAGATCGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAGGAG 2340
QY 781 TyrAlaSerIleAspIleSerLysGlyGluAsnAsnProGlyPheGlnAsnThrAspAsp 800
Db 2341 TATGCCTCCATCATATTAGCAAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 2400
QY 801 ValGlnThrSerPhe 805
Db 2401 GTTCAGACCTCCCTTT 2415
RESULT 2
AAC84366
ID AAC84366 standard; cDNA; 3334 BP.
XX
AC AAC84366;
XX
XX 19-MAR-2001 (first entry)
XX
XX Human Zace2 protein encoding cDNA.
XX
XX Zace2; metalloenzyme; angiotensin-converting enzyme; ACE; fertility;
XX zinc metalloproteinase; blood pressure; zinc protease; hypertension;
XX ventricular systolic dysfunction; renal impairment; heart failure;
XX scleroderma renal crisis; atherosclerosis; antiinflammatory; human;
XX antiarthritic; bradykinin inactivator; ss.
XX
XX Homo sapiens.
XX
XX
XX
XX Key Location/Qualifiers

CDS 35..2452
FT FT /tag- a "zace2"
FT FT /product- "zace2"
PN PN WO200070032-A1.
XX 23-NOV-2000.
XX 03-MAY-2000; 2000WO-US11932.
XX 13-MAY-1999; 99US-0311482.
XX 21-AUG-1999; 99US-0384706.
XX (ZYMO) ZYMOGENETICS INC.
XX Piddington CS, Petrie CR, Shoemaker KE, Bishop PD;
XX WPI; 2001-025018/03.
XX P-PDB; AAB48095.
XX
XX Angiotensin-converting enzyme, Zace2, useful for treating inflammatory
XX bowel disease, e.g. Crohn's disease and ulcerative colitis, or diseases
XX associated with inflammation such as arthritis and enterocolitis -
XX Example 1; Page 95-100; 125pp; English.
XX
XX The invention relates to the metalloenzyme Zace2. Zace2, an angiotensin-
XX converting enzyme is a zinc metalloproteinase that plays roles in blood
XX pressure regulation and fertility. Zace2 can be expressed by standard
XX recombinant methodology. Zace2 polypeptides are useful for treating an
XX inflammatory bowel disease (e.g. Crohn's disease and ulcerative colitis),
XX diseases associated with inflammation like arthritis and enterocolitis,
XX as targets for identifying modulators of zinc protease activity, for
XX screening or identifying new angiotensin-converting enzyme (ACE)
XX inhibitors, and as a basis for rational drug design for inhibitory
XX molecules. The nucleic acids can be used to detect the expression of a
XX Zace2 gene in a biological sample, as probes for in vivo diagnosis and
XX for detecting and localizing Zace2 gene expression in tissue samples,
XX to determine whether a subject's chromosomes contain a mutation in the
XX Zace2 gene, and to detect aberrations associated with the Zace2 locus.
XX Inhibitors of ACE are used for treating hypertension of various
XX conditions, including left ventricular systolic dysfunction, progressive
XX renal impairment, scleroderma renal crisis, congestive heart failure due
XX to dysfunction, and treatment of atherosclerosis. Zace2 agonists may be
XX used to treat infertility while Zace2 antagonists are used for inducing
XX infertility. The present sequence represents a cDNA encoding the human
XX Zace2 protein.
XX
XX Sequence 3334 BP; 1011 A; 640 C; 754 G; 929 T; 0 other;
SQ
Alignment Scores:
Pred. No.: 0 Length: 3334
Score: 4291.00 Matches: 805
Percent Similarity: 100.00% Conservative: 0
Best Local Similarity: 100.00% Mismatches: 0
Query Match: 100.00% Indels: 0
DB: 22 Gaps: 0
US-09-635-501-2 (1-805) x AAC84366 (1-3334)
QY 1 MetSerSerSerTrpLeuLeuLeuSerLeuValAlaValThrAlaAlaGlnSerThr 20
DB 35 ATGTCAAGCTCTTCTGGCTCTCTCAGCCTTGTGTGCTGTAACCTGCTCAGTCCACC 94
QY 21 IleGluGlnAlaLysThrPheLeuAspLysPheAsnHisGluAlaGluAspLeuPhe 40
DB 95 ATTGAGGAACAGCCCAAGACATTTTGGACAAAGTTTAAACCAAGCCGAGACCTGTC 154
QY 41 TyrGlnSerSerLeuAlaSerTrpAsnTyrAsnThrAsnIleThrGluGluAsnValGln 60
DB 155 TATCAAGTTCACCTTCTTGGAAATTTATACACCATATTTACTGAGAGAAATGTCCTCA 214
QY 61 AsnMetAsnAsnAlaGlyAspLysTrpSerAlaPheLeuLysGluGlnSerThrLeuAla 80

|||||
Db 215 AACATGAATAATGCTGGGACAAATGGTCTGCTTTTAAAGGAACAGCTCCACACTTGGC 274
Qy 81 GlnMetTyrProLeuGlnGlnGlnAsnLeuThrValLysLeuGlnLeuAlaLeu 100
Db 275 CAATGTATCCACTACCAAGAAATTCAGAAATCTCACAGCTCAAGCTTCAGCTCGACGCTCTT 334
Qy 101 GlnGlnAsnGlySerSerValLeuSerGluAspLysSerLysArgLeuAsnThrIleLeu 120
Db 335 CAGCAAAATGGGTCTTCAGTGTCTCTCAGAAGACAAAGACAAACGGTTGAACACAATCTA 394
Qy 121 AsnThrMetSerThrIleTyrSerThrGlyLysValLysAsnProAspAsnProGlnGlu 140
Db 395 AATCAATGAGCACCATCTACAGTACTGGAAAGTTTGAACCCAGATTAATCCACAAGA 454
Qy 141 CysLeuLeuLeuGluProGlyLeuAsnGluIleMetAlaAsnSerLeuAspTyrAsnGlu 160
Db 455 TGCTTATTACTTGAACACAGGTTTGAATGAATAATGGCAACAGCTTTAGACTACAATGAG 514
Qy 161 ArgLeuTrpAlaTyrGluSerTrpArgSerGluValGlyLysGlnLeuArgProLeuTyr 180
Db 515 AGGCTCTGGGCTTGGGAAGCTGGAGATCTGAGGTGGCAAGCAGCTGAGGCCATTTAT 574
Qy 181 GluGluTyrValValLeuLysAsnGluMetAlaArgAlaAsnHisTyrGluAspTyrGly 200
Db 575 GAAGAGTATGTGTCTTGAATAATGAGATGGCAAGAGCAAAATCATTTATGAGGACTATGGG 634
Qy 201 AspTyrTrpArgGlyAspTyrGluValAsnGlyValLaspGlyTyrAspTyrSerArgGly 220
Db 635 GATTATTGGAGAGGAGACTATGAATGAATGGGTAGATGGCTATGACTACAGCCGCGGC 694
Qy 221 GlnLeuIleGluAspValGluHisThrPheGluGluIleLysProLeuTyrGluHisLeu 240
Db 695 CAGTTGATTGAAGATGTGGAACTACTCTTGAAGAGATTAAACCAATTATATGAACATCTT 754
Qy 241 HisAlaTyrValArgAlaLysLeuMetAsnAlaTyrProSerTyrIleSerProIleGly 260
Db 755 CATGCCTATGTGAGGCAAAATGATGAATGGCTATCTCTCTATATCAGTCCCAATTGA 814
Qy 261 CysLeuProAlaHisLeuLeuGlyAspMetTrpGlyArgPheTrpThrAsnLeuTyrSer 280
Db 815 TGCCCTCCCTGCTCATTTGCTTGGTGATATGTGGGTAGATTTTGGACAAATCTGTACTCT 874
Qy 281 LeuThrValProPheGlyGlnLysProAsnIleAspValThrAspAlaMetValAspGln 300
Db 875 TTGACAGTCTCCTTTGGACAGAAACCAACATAGATGTTACTGATGCAATGTTGGACAG 934
Qy 301 AlaTrpAlaGlnArgIlePheLysGluAlaGluLysPhePheValSerValGlyLeu 320
Db 935 GCCTGGGATGCACAGAGAAATTTCAAGGAGGCGGAGAGTTCTTTGTATCTGTGGTCTT 994
Qy 321 ProAsnMetThrGlnGlyPheTrpGluAsnSerMetLeuThrAspProGlyAsnValGln 340
Db 995 CCTAATATGACTCAAGGATTTCTGGAAATTTCCATGCTAACGGACCCAGGAAATGTTTCAG 1054
Qy 341 LysAlaValCysHisProThrAlaTrpAspLeuGlyLysGlyAspPheArgIleLeuMet 360
Db 1055 AAAGCAGTCTGCCATCCACAGCTTGGACCTGGGAGGCGGAGCTTCAGGATCCTTATG 1114
Qy 361 CysThrLysValThrMetAspAspPheLeuThrAlaHisHisGluMetGlyHisIleGln 380
Db 1115 TGCACAAAGGTGCAATGGAGCAGCTTCTTCACAGCTCATCATGAGATGGGCAATCCAG 1174
Qy 381 TyrAspMetAlaTyrAlaAlaGlnProPheLeuLeuArgAsnGlyAlaAsnGluGlyPhe 400
Db 1175 TATGATATGGCATATGTGCACAACTTTCTGCTAAGAAATGGAGCTTAATCAAGGATTC 1234
Qy 401 HisGluAlaValGlyGluIleMetSerLeuSerAlaAlaThrProLysHisLeuLysSer 420
Db 1235 CATGAAGCTGTGGGAAATCATGTCACTTCTGCAGGCCACACCTTAAGCAATTTAAATCC 1294
Qy 421 IleGlyLeuLeuSerProAspPheGlnGluAspAsnGluThrGluIleAsnPheLeuLeu 440
|||||

Db 1295 ATTGGTCTTCTGTACCCCGATTTTCAAGAAGACAAATGAACAGAAATAAACTTCTCTCTC 1354
Qy 441 LysGlnAlaLeuThrIleValGlyThrLeuProPheThrTyrMetLeuGluLysTyrArg 460
Db 1355 AAACAAGCACTCAGATTTTGGGACTCTGCCATTTACTTACATGTTAGACAAGTGAGG 1414
Qy 461 TrpMetValPheLysGlyGluIleProLysAspGlnTrpMetLysLysTyrTrpGluMet 480
Db 1415 TCGATGTCTTTAAAGGGGAAATTTCCCAAAGCAGCTGGATGAAAGTGGTGGGATG 1474
Qy 481 LysArgGluIleValGlyValValGluProValProHisAspGluThrTyrCysAspPro 500
Db 1475 AAGCGAGAGATAGTGGGTGGTGGAACTGTGCCCATGATGAACATACTGTGACCCC 1534
Qy 501 AlaSerLeuPheHisValSerAsnAspTyrSerPheIleArgTyrTyrThrArgThrLeu 520
Db 1535 GCATCTCTGTCTCCATGTTCTAATGATTACTCATTCATTCTCGATATTACAAAGACCCCT 1594
Qy 521 TyrGlnPheGlnPheGlnGluAlaLeuCysGlnAlaAlaLysHisGluGlyProLeuHis 540
Db 1595 TACCAATTCAGTTTCAAGAAAGCACCTTTGTCAAGCAGCTAAACATGAAGGCCCTCTGCAC 1654
Qy 541 LysCysAspIleSerAsnSerThrGluAlaGlyGlnLysLeuPheAsnMetLeuArgLeu 560
Db 1655 AAATGTGACATCTCAAACTCTACAGAGCTGGACAGAACTGTTCAATATGCTGAGGCTT 1714
Qy 561 GlyLysSerGluProTrpThrLeuAlaLeuGluAsnValValGlyAlaLysAsnMetAsn 580
Db 1715 GGAATTCAGAACCTTGACCTAGCATTTGGAATTTGTTAGGAGCAACAAACATGAAT 1774
Qy 581 ValArgProLeuLeuAsnTyrPheGluProLeuPheThrTrpLeuLysAspGlnAsnLys 600
Db 1775 GTAAGGCCACTGTCTCAACTACTTTGAGCCCTTATTACTTGCTGAAAGACCAAGCAAG 1834
Qy 601 AsnSerPheValGlyTrpSerThrAspTrpSerProTyrAlaAspGlnSerIleLysVal 620
Db 1835 AATCTTTTGGGTGGTGGTACCGACTGGATGCCATATGCAGACCAAGCATCAAGTG 1894
Qy 621 ArgIleSerLeuLysSerAlaLeuGlyAspLysAlaTyrGluTrpAsnAspAsnGluMet 640
Db 1895 AGGATAGCCCTAAATCAGCTCTTGGAGATAAAGCATATGAATGAAGACGACAAATGAATG 1954
Qy 641 TyrLeuPheArgSerSerValAlaTyrAlaMetArgGlnTyrPheLeuLysValLysAsn 660
Db 1955 TACTGTTCGCGATCATCTGTTCATATGCTATGAGCGAGTACTTTTAAAGTAAAAAT 2014
Qy 661 GlnMetIleLeuPheGlyGluGluAspValArgValAlaAsnLeuLysProArgIleSer 680
Db 2015 CAGATGATCTTTTGGGGAGGAGGATGCGGAGTGCTTAATTTGAAACCAAGAAATCTCC 2074
Qy 681 PheAsnPhePheValThrAlaProLysAsnValSerAspIleIleProArgThrGluVal 700
Db 2075 TTTAATTTCTTTGTCACCTGCACCTTAAATGTCTGTGATATCATCTCTAGAACTGAAGTT 2134
Qy 701 GluLysAlaIleArgMetSerArgSerArgIleAsnAspAlaPheArgLeuAsnAspAsn 720
Db 2135 GAAAGGCCATCAGATGTCCCGAGCCGCTATCAATGATGCTTCCTGCTGAAATGACAAAC 2194
Qy 721 SerLeuGluPheLeuGlyIleGlnProThrLeuGlyProProAsnGlnProProValSer 740
Db 2195 AGCCTAGAGTTTCTGGGATACAGCCAAACACTTGGACCTCTCTAACCGCCCTGTTTCC 2254
Qy 741 IleTrpLeuIleValPheGlyValValMetGlyValIleValValGlyIleValLeu 760
Db 2255 ATATGGCTGTATGTTTGGAGTTGTGATGGGAGTGATAGTGGTGTGGCATTTGTCTATCTG 2314
Qy 761 IlePheThrGlyIleArgAspArgLysLysLysAsnLysAlaArgSerGlyGluAsnPro 780
Db 2315 ATCTTCACTGGGATCAGAGATCGGAAGAGAAAAATAAAGCAAGAGTGGAGAAATCCT 2374
Qy 781 TyrAlaSerIleAspIleSerLysGlyGluAsnProGlyPheGlnAsnThrAspAsp 800
Db 2375 TATGCCCTCATGATATTAGCAAGGAGAAATAATATCCAGGATTTCCAAACACATGATGAT 2434

QY 801 ValGlnThrSerPhe 805
 Db 2435 GTTCAGACCTCCTTT 2449
 RESULT 3
 AAA12764
 ID AAA12764 standard; cDNA; 3396 BP.
 XX
 AC AAA12764;
 XX
 XX 25-JUL-2000 (first entry)
 XX cDNA encoding a human angiotensin converting enzyme-2 (ACE-2).
 DE
 XX Human; angiotensin converting enzyme-2; ACE-2; angiotensin I; Ang.(1-9);
 KW blood pressure; hypertension; congestive heart failure; atherosclerosis;
 KW chronic heart failure; acute heart failure; myocardial infarction;
 KW renal failure; ss.
 KW
 XX Homo sapiens.
 OS
 FH Key Location/Qualifiers
 FT CDS 82..2499
 FT /*tag= a
 FT /product= "angiotensin converting enzyme-2"
 FT sig_peptide 82..135
 FT /*tag= b
 XX
 PN WO200018899-A2.
 XX
 XX 06-APR-2000.
 PD
 XX
 XX 29-SEP-1999; 99WO-US22976.
 PF
 XX 30-SEP-1998; 98US-0163648.
 PR
 XX (MILL-) MILLENNIUM PHARM INC.
 PA
 XX Acton LS, Robison KE, Hsieh FY;
 PI P-PSDB; AAY84562.
 XX
 XX WPI; 2000-293140/25.
 DR
 DR
 XX Isolated nucleic acid encoding angiotensin converting enzyme-2 (ACE-2)
 PT polypeptide useful for detecting an ACE-2 therapeutic for treating
 PT hypertension, congestive heart failure, myocardial infarction,
 PT atherosclerosis and renal failure -
 XX
 XX Claim 1; Fig 1; 138pp; English.
 PS
 XX The present sequence encodes a human angiotensin converting enzyme-2
 CC (ACE-2). ACE-2 is expressed predominantly in kidneys and testis. The
 CC sequence of the full length ACE-2 cDNA was determined from a clone
 CC obtained from a cDNA library prepared from mRNA of a human heart of
 CC a subject who had congestive heart failure. ACE-2 has significant
 CC sequence homologies with ACE enzymes, and has also been shown to
 CC hydrolyse angiotensin I into Ang.(1-9). The ACE-2 therapeutics are
 CC used to treat blood pressure related diseases and conditions, such as
 CC hypertension, congestive heart failure, chronic heart failure, acute
 CC heart failure, myocardial infarction, atherosclerosis and renal
 CC failure.
 XX
 SQ Sequence 3396 BP; 1034 A; 660 C; 771 G; 931 T; 0 other;
 Alignment Scores:
 Pred. No.: 0 Length: 3396
 Score: 4291.00 Matches: 805
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 21 Gaps: 0

US-09-635-501-2 (1-805) x AAA12764 (1-3396)
 QY 1 MetSerSerSerSerTrpLeuLeuSerLeuValAlaValThrAlaAlaGlnSerThr 20
 |||||
 Db 82 ATGTCAAGCTCTTCTGCTCTCTGCTCTCTGCTCTCTGCTCTCTGCTCTCTGCTCT 141
 |||||
 QY 21 IleGluGluGlnAlaLysThrPheLeuAspLysPheAsnHisGluAlaGluAspLeuPhe 40
 |||||
 Db 142 ATTGAGGAACAGCCCAAGACATTTTGGCAAGTTTAAACACGAAGCCGAAGACCTGTC 201
 |||||
 QY 41 TyrGlnSerSerLeuAlaSerTrpAsnThrAsnThrGluGluAsnValGln 60
 |||||
 Db 202 TATCAAGTTCACCTGCTCTTGGAAATATACACCAATATATTCTGAAGAAATGTCCAA 261
 |||||
 QY 61 AsnMetAsnAlaGlyAspLysTrpSerAlaPheLeuLysGluGlnSerThrLeuAla 80
 |||||
 Db 262 AACATGAATATGCTGGGACAAATGGTCTGCTCTTTTAAAGGAACAGTCCACACTGGCC 321
 |||||
 QY 81 GlnMetTyrProLeuGlnGluIleGlnAsnLeuThrValLysLeuGlnLeuAlaLeu 100
 |||||
 Db 322 CAATGTATCCACTACAGAAATTCGAAATCTCACAGTCAAGCTTCAGCTGCAAGCTCTT 381
 |||||
 QY 101 GlnGlnAsnGlySerSerValLeuSerGluAspLysSerLysArgLeuAsnThrLeu 120
 |||||
 Db 382 CAGCAAAATGGGTCTTCACTGCTCTCAGACACAAGAGCAAAACGGTTGAACAATCTGA 441
 |||||
 QY 121 AsnThrMetSerThrIleTyrSerThrGlyLysValCysAsnProAspAsnProGlnGlu 140
 |||||
 Db 442 AATCAATGAGCACCATCTACAGTACTCGAAAGTTGTAAACCCAGATAATATCCACAGAA 501
 |||||
 QY 141 CysLeuLeuGluProGlyLeuAsnGluIleMetAlaAsnSerLeuAspTyrAsnGlu 160
 |||||
 Db 502 TGCTTATTACTTGAACAGGTTTGAATGAATAATGCAAAACAGTTTATAGACTACAATGAG 561
 |||||
 QY 161 ArgLeuTrpAlaTrpGluSerTrpArgSerGluValGlyLysGlnLeuArgProLeuTyr 180
 |||||
 Db 562 AGGCTCTGGGCTGGGAAAGCTGGAGATCTGAGGTGCGCAAGCAGCTGAGGCCATTATAT 621
 |||||
 QY 181 GluGluTyrValValLeuLysAsnGluMetAlaArgAlaAsnHisTyrGluAspTyrGly 200
 |||||
 Db 622 GAAGAGTATGTGCTTGAATAATGAGATGCAAGAGCAAAATCATATTATGAGGACTATGGS 681
 |||||
 QY 201 AspTyrTrpArgGlyAspTyrGluValAsnGlyValAspGlyTyrAspTyrSerArgGly 220
 |||||
 Db 682 GATTATTGGAGAGGAGACTATGAAGTAAATGGGTAGATGGCTATGACTACAGCCCGCGC 741
 |||||
 QY 221 GlnLeuIleGluAspValGluHisThrPheGluGluIleLysProLeuTyrGluHisLeu 240
 |||||
 Db 742 CAGTTGATTGAAGATGTGGAACATACCTTTCAAGAGATTAAACCATTTATATGAACATCTT 801
 |||||
 QY 241 HisAlaTyrValArgAlaLysLeuMetAsnAlaTyrProSerTyrIleSerProIleGly 260
 |||||
 Db 802 CATGCCATGTGAGGGCAAGTTGATGAATGCCCTATCTCTCTATATCATGTCGAATGGA 861
 |||||
 QY 261 CysLeuProAlaHisLeuLeuGlyAspMetTrpGlyArgPheThrAsnLeuTyrSer 280
 |||||
 Db 862 TGCTCCCTGCTCACTTCTGCTGATATGCGGTAGATTTGGACAAATCTGTACTCT 921
 |||||
 QY 281 LeuThrValProPheGlyGlnLysProAsnIleAspValThrAspAlaMetValAspGln 300
 |||||
 Db 922 TTGACAGTTCCCTTTGGACAGAAACCAACATAGATCTTACTGATGCAATGTGTGGACAG 981
 |||||
 QY 301 AlaTrpAspAlaGlnArgIlePheLysGluAlaGluLysPheValSerValGlyLeu 320
 |||||
 Db 982 GCCTGGGATGCACAGAAATATCAAGAGGCCGAGAAAGTTCTTGTATCTGTGTGCTCTT 1041
 |||||
 QY 321 ProAsnMetThrGlnGlyPheTrpGluAsnSerMetLeuThrAspProGlyAsnValGln 340
 |||||
 Db 1042 CCTAATATGACTCAAGGATTTCTGGGAAATTTCCATGTCACGGACCCAGGAAATGTTGAG 1101
 |||||
 QY 341 LysAlaValCysHisProThrAlaTrpAspLeuGlyLysGlyAspPheArgIleLeuMet 360
 |||||
 Db 1102 AAAGCAGTCTGCCATCCACACACTTGGGACCTGGGAGGGGCGGACCTTCAGGATCCTTATG 1161
 |||||

QY 361 CysThrLysValThrMetAspAspPheLeuThrAlaHisHisGluMetGlyHisIleGln 380
DB 1162 TCACAAAGGTGACAAATGGAGACCTTCCGACAGCTCATCATGATGGGCAATATCCAG 1221
QY 381 TyrAspMetAlaTyrAlaAlaGlnProPheLeuLeuArgAsnGlyAlaAsnGluGlyPhe 400
DB 1222 TATGATATGGCATATGCTGCACAACTTTCTCTGAAGAAATGGAGCTTAATGAAGGATTC 1281
QY 401 HisGluAlaValGlyGluIleMetSerLeuSerAlaAlaThrProLysHisLeuLysSer 420
DB 1282 CATGAAGCTGTGGGAAATCATGCTACTTCGACGCCACACCTTAAGCATTTAAATATCC 1341
QY 421 IleGlyLeuLeuSerProAspPheGlnGluAspAsnGluThrGluIleAsnPheLeuLeu 440
DB 1342 ATTGGTCTTCTGTCCACCGATTTTCAAGAGACAAATGAACAGAAATAAATCTCTGCTC 1401
QY 441 LysGlnAlaLeuThrIleValGlyThrLeuProPheThrTyrMetLeuGluLysTyrArg 460
DB 1402 AAACAAGCACTCAGCATTTGGGACTCTGCCATTTACTTACATGTTAGAGAAGTGGAGG 1461
QY 461 TrpMetValPheLysGlyGluIleProLysAspGlnTrpMetLysLysTyrTrpGluMet 480
DB 1462 TGGATGGTCTTTAAAGGGGAAATTCCTCAAGACCAAGTGGATGAAAGAGTGGGAGATG 1521
QY 481 LysArgGluIleValGlyValValGluProValProHisAspGluThrTyrCysAspPro 500
DB 1522 AAGCGAGAGATAGTTGGGGTGGTGGAACTGTGCCCATGATGAACATATCTGTGACCCC 1581
QY 501 AlaSerLeuPheHisValSerAsnAspTyrSerPheIleArgTyrTyrThrArgThrLeu 520
DB 1582 GCATCTCTGTTCCTCATTTCTTAATGATTTACTCATTCATTCGATATTCACCAAGACCCCTT 1641
QY 521 TyrGlnPheGlnPheGlnGluAlaLeuCysGlnAlaAlaLysHisGluGlyProLeuHis 540
DB 1642 TACCAATTTCCAGTTTCAAGAGCACCTTGTCAAGCAGCTTAACATGAAGGCCCTCTGCAC 1701
QY 541 LysCysAspIleSerAsnSerThrGluAlaGlyGlnLysLeuPheAsnMetLeuArgLeu 560
DB 1702 AATGTGACATCTCAAACTCTACAGAAGCTGGACAGAACTCTTCAATATGCTGAGGCTT 1761
QY 561 GlyLysSerGluProTrpThrLeuAlaLeuGluAlaAsnValValGlyAlaLysAsnMetAsn 580
DB 1762 GGAATAATCAGAAACCTGGACCTAGCATTTGGAAATGTTGTAGGAGCAAGAAACATGAAT 1821
QY 581 ValArgProLeuLeuAsnTyrPheGluProLeuPheThrTrpLeuLysAspGlnAsnLys 600
DB 1822 GTAAGCCACTGCTCAACTACTTTGAGCCCTTATTTACCTGCTGAAAGACCAAGCAAG 1881
QY 601 AsnSerPheValGlyTrpSerThrAspTrpSerProTyrAlaAspGlnSerIleLysVal 620
DB 1882 AATTTCTTTTGGGATGGAGTACCGACTGGAGTCCATATGCAAGCAAAAGCATCAAAAGTG 1941
QY 621 ArgIleSerLeuLysSerAlaLeuGlyAspLysAlaTyrGluTrpAsnAspAsnGluMet 640
DB 1942 AGGATAAGCCTTAATCAGCTCTTGGAGATAAGCATATGAATGAAGCAACATGAATG 2001
QY 641 TyrLeuPheArgSerValAlaTyrAlaMetArgGlnTyrPheLeuLysValLysAsn 660
DB 2002 TACCTGTTCGATCATCTGTTCATATGCTATGAGCGAGTACTTTTAAAGTAAAAAAT 2061
QY 661 GlnMetIleLeuPheGlyGluLysAspValArgValAlaAsnLeuLysProArgIleSer 680
DB 2062 CAGATGATCTTTTGGGAGGAGGATGTCCGAGTGGCTAATTTGAAACCAAGATATCC 2121
QY 681 PheAsnPheValThrAlaProLysAsnValSerAspIleIleProArgThrGluVal 700
DB 2122 TTTAATTTCTTTGTCACTGCACCTTAAATATGTCTGTATATCATTCCTAGAACCTGAAGTT 2181
QY 701 GluLysAlaIleArgMetSerArgSerArgIleAsnAspAlaPheArgLeuAsnAspAsn 720
DB 2182 GAAAGGCCATCAGAGTCTCCGAGGCCGCTATCATATGATGCTTCCGTCTGAATGACAAC 2241

QY 721 SerLeuGluPheLeuGlyIleGlnProThrLeuGlyProProAsnGlnProProValSer 740
DB 2242 AGCTAGATTTCTGGGATACAGCCACACCTTGGACCTCTTAACAGCCCTGTTTCC 2301
QY 741 IleTrpLeuIleValPheGlyValValMetGlyValIleValValGlyIleValIleLeu 760
DB 2302 ATATGGCTGATTTGTTTGGAGTTGTGATGGGAGTGATAGTGGTGGCATTTGTCATCTG 2361
QY 761 IlePheThrGlyIleArgAspArgLysLysLysLysAsnLysAlaArgSerGlyGluAsnPro 780
DB 2362 ATCTTCACTGGGATCAGACATCGGAAGAAGAAATAAAGCAAGAGTGGAGAAATCCT 2421
QY 781 TyrAlaSerIleAspIleSerLysGlyGluAsnAsnProGlyPheGlnAsnThrAspAsp 800
DB 2422 TATGCCCTCCATCGATATAGCAAGGAGAAATAATCCAGGATTTCCAAACACTGATGAT 2481
QY 801 ValGlnThrSerPhe 805
DB 2482 GTTCAGACCTCCTTT 2496
RESULT 4
AAD02758
ID AAD02758 standard; cDNA; 3396 BP.
XX
AC AAD02758;
XX
DT 31-MAY-2001 (first entry)
XX
DE Human angiotensin converting enzyme-2 (ACE-2) cDNA.
XX
KW Human; angiotensin converting enzyme-2; ACE-2; peptidyl dipeptidase A;
KW screening; therapy; hypertension; congestive heart failure; CHF;
KW inflammation; pain; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT CDS 82..2499
FT /tag= a
FT /product= "Human angiotensin converting enzyme-2
FT (ACE-2)"
FT /EC_number= "3.4.15.1"
FT /note= "This region is referred as SEQ.ID.NO.3 and is
FT specifically claimed in claim 26"
FT sig_peptide 82..135
FT /tag= b
FT mat_peptide 136..2496
FT /tag= c
FT /product= "Human mature angiotensin converting enzyme-2
FT (ACE-2)"
XX
PN US6194556-B1.
XX
PD 27-FEB-2001.
XX
PF 11-DEC-1997; 97US-0989299.
XX
PR 11-DEC-1997; 97US-0989299.
XX
PA (MILL-) MILLENNIUM PHARM INC.
XX
PI Acton SL, Robison KE;
XX
DR WPI; 2001-210604/21.
XX P-PSDB; AAY72667.
XX
PT Novel genes encoding angiotensin converting enzyme-2 useful as
PT antisense or anti gene agents for therapeutics, diagnostics and
PT screening assays -
XX
PS Claim 1; Fig 1; 76pp; English.
XX
CC The present sequence is human angiotensin converting enzyme-2 (ACE-2)

CC cDNA. ACE is also referred as peptidyl dipeptidase A. Nucleic acid
 CC sequence encoding ACE-2 is useful as antisense or antigenic agents for
 CC sequence specific modulation of gene expression or in the analysis of
 CC single base-pair mutations in the gene. Nucleic acid sequence encoding
 CC ACE-2 is useful in therapeutics, diagnostics and in screening assays.
 CC ACE-2 antagonist is used to treat hypertension or congestive heart
 CC failure (CHF). ACE agonist is used to reduce the inflammation and pain
 CC resulting from an insect sting or bite, which was accompanied by an
 CC injection of bradykinin. Anti-ACE-2 antibodies are used to monitor ACE-2
 CC protein levels for determining the disease or condition associated with
 CC an aberrant protein level.
 XX
 SQ Sequence 3396 BP; 1034 A; 659 C; 772 G; 931 T; 0 other;

Alignment Scores:
 Pred. No.: 0 Length: 3396
 Score: 4291.00 Matches: 805
 Percent Similarity: 100.00% Conservative: 0
 Best Local Similarity: 100.00% Mismatches: 0
 Query Match: 100.00% Indels: 0
 DB: 22 Gaps: 0

US-09-635-501-2 (1-805) x AAD02758 (1-3396)

Qy 1 MetSerSerSerTrpLeuLeuLeuSerLeuValAlaValThrAlaAlaGlnSerThr 20
 Db 82 ATGTCAAGCTCTTCTGGGCTCTCTCAGCCCTTGTGCTGTAATGCTGCTCAGTCACCC 141
 Qy 21 IleGluGlnAlaLysThrPheLeuAspLysPheAsnHisGluAlaGluAspLeuPhe 40
 Db 142 ATTGAGGACAGCCCAAGACATTTTGGACAAAGTTTAACCCAGCAAGCGGAGACCTGTC 201
 Qy 41 TyrGlnSerSerLeuAlaSerTrpAsnTrpAsnThrAsnThrGluGluAsnValGln 60
 Db 202 TATCAAGTTCACCTGCTCTTGGAAATATTAACACCAATATTAATGAGGAATGTCCTCA 261
 Qy 61 AsnMetAsnAlaGlyAspLysTrpSerAlaPheLeuLysGluGlnSerThrLeuAla 80
 Db 262 AACATGAATTAATGCTGGGACAAATGGTCTGCTCTTTTAAAGGAACACGTCACACTTGC 321
 Qy 81 GlnMetTrpProLeuGlnGluGlnAsnLeuThrValLysLeuGlnLeuGlnAlaLeu 100
 Db 322 CAATGTATCCACTACAAGAAATTCAGAAATCTCAGACGTCAAGCTTCAGCTGCAGGCTCT 381
 Qy 101 GlnGlnAsnGlySerValLeuSerGluAspLysSerLysArgLeuAsnThrIleLeu 120
 Db 382 CAGCAAAATGGGTCTTCACTGCTGTGAGAGATCTGAGGTGCGGCAAGACGCTTGAACAAATCTCA 441
 Qy 121 AsnThrMetSerThrIleTrpSerThrGlyLysValCysAsnProAspAsnProGlnGlu 140
 Db 442 AATACAATGAGCACCACTACAGTACTGGAAGANGTTTGAACCCAGATAATCCACAAGAA 501
 Qy 141 CysLeuLeuLeuGluProGlyLeuAsnGluIleMetAlaAsnSerLeuAspTrpAsnGlu 160
 Db 502 TGCTTATTAATTAACACGAGTTTGAATGAATAATGCAACAGCTTTAGACTACAAATGAG 561
 Qy 161 ArgLeuTrpAlaTrpGluSerTrpArgSerGluValGlyLysGlnLeuArgProLeuTrp 180
 Db 562 AGGCTCTGGGCTTGGGAAGCTTGGAGATCTGAGGTGCGGCAAGACGCTGAGGCCATTATAT 621
 Qy 181 GluGluTrpValValLeuLysAsnGluMetAlaArgAlaAsnHisTyrGluAspTrpGly 200
 Db 622 GAAGAGTATGTGCTTGGAAATGAGATGGAAGAGCAAGCAATATTAATGAGGACTATGGG 681
 Qy 201 AspTrpTrpArgGlyAspTrpGluValAsnGlyValAspGlyTyrAspTrpSerArgGly 220
 Db 682 GATTATTTGGAGAGGACATATGAAGTAAATGGGGTAGATGGCTATGACTACAGCCGGGGC 741
 Qy 221 GlnLeuIleGluAspValGluHisThrPheGluGluIleLysProLeuTrpGluHisLeu 240
 Db 742 CAGTTGATTCAAGATCTGGAACATACCTTTGAAGAGATTAAACCATATATGAACATCTT 801
 Qy 241 HisAlaTrpValArgAlaLysLeuMetAsnAlaTrpProSerTrpIleSerProIleGly 260

Db 802 CATGCCTATGTGAGGCAAGATTGATGAATGCTATCTCTCTATATCAGTCAATTTGGA 861
 Qy 261 CysLeuProAlaHisLeuLeuGlyAspMetTrpGlyArgPheTrpThrAsnLeuTrpSer 280
 Db 862 TGCCTCCTCCTCATTTGCTTGTGTATATGTGGGTAGATTGTGGACAAATCTGTACTCT 921
 Qy 281 LeuThrValProPheGlyGlnLysProAsnIleAspValThrAspAlaMetValAspGln 300
 Db 922 TTGACACTTCCCTTTGGACAGAAACCAACATAGATGTTACTGATGCAATGGTGGACCAG 981
 Qy 301 AlaTrpAspAlaGlnArgIlePheLysGluAlaGluLysPhePheValSerValGlyLeu 320
 Db 982 GCCTGGGATGCACAGAGAATATTCAAGAGGCGCGAGAAGTCTCTTTGTATCTGTGGTCTT 1041
 Qy 321 ProAsnMetThrGlnGlyPheTrpGluAsnSerMetLeuThrAspProGlyAsnValGln 340
 Db 1042 CCTATATGACTCAGGATCTGGGAAATTCATGCTPACCGACCCAGGAAATGTTTCAG 1101
 Qy 341 LysAlaValCysHisProThrAlaTrpAspLeuGlyLysGlyAspPheArgIleLeuMet 360
 Db 1102 AAGCAGCTCTGCCATCCACAGCTTGGGACCTGGGGAAGGGGAGCTTCAGGATCCTTATG 1161
 Qy 361 CysThrLysValThrMetAspPheLeuThrAlaHisHisGluMetGlyHisIleGln 380
 Db 1162 TGCACAAAGGTGACATGACGACTTCTTGACAGCTCATCATGAGTGGGCGCATATCCAG 1221
 Qy 381 TyrAspMetAlaTrpAlaAlaGlnProPheLeuLeuArgAsnGlyAlaAsnGluGlyPhe 400
 Db 1222 TATGATATGTCATATGCTGCACAACTTTTCTGCTAAGAAATGGAGCTTAATGAAGGATTC 1281
 Qy 401 HisGluAlaValGlyLueIleMetSerLeuSerAlaAlaThrProLysHisLeuLysSer 420
 Db 1282 CATGAACCTGTTGGGAAATCATGTCACCTTCTGCAGCCACACCTTAACATCTTAAATCC 1341
 Qy 421 IleGlyLeuLeuSerProAspPheGlnGluAspAsnGluThrGluIleAsnPheLeuLeu 440
 Db 1342 ATTTGGTCTTGTGTCACCCGATTTTCAAGAGACAAATGAACAGAAATAAATCTCTGCTC 1401
 Qy 441 LysGlnAlaLeuThrIleValGlyThrLeuProPheThrTyrMetLeuGluLysTrpArg 460
 Db 1402 AAACAACGACTCAGATTTGTTGGGACTCTGCCATTTACTTACATTTAGAGAAAGTGGAGG 1461
 Qy 461 TrpMetValPheLysGlyGluIleProLysAspGlnTrpMetLysLysTrpTrpGluMet 480
 Db 1462 TGGATGTCTTTAAAGGGGAAATTCCTCAAGACACAGTGGATGAAAGTGGTGGGAGATG 1521
 Qy 481 LysArgGluIleValGlyValValGluProValProHisAspGluThrTyrCysAspPro 500
 Db 1522 AAGCGAGAGATAGTTGGGTGGTGGAACTGTGCCCATGATGAACACATATCTGTGACCCC 1581
 Qy 501 AlaSerLeuPheHisValSerAsnAspTyrSerPheIleArgTyrTrpArgThrIleu 520
 Db 1582 GCATCTCTGTCTCATATGTTCTAATGATTACTCATTCATTTCGATATTACAAAGACCTTT 1641
 Qy 521 TyrGlnPheGlnPheGlnGluAlaLeuCysGlnAlaAlaLysHisGluGlyProLeuHis 540
 Db 1642 TACCAATTCAGTTTCAAGAACGCTTTGTCAAGCAGCTTAACATGAAGGCCCTCTGCAC 1701
 Qy 541 LysCysAspIleSerAsnSerThrGluAlaGlyGlnLysLeuPheAsnMetLeuArgLeu 560
 Db 1702 AAATGTGACATCTCAAACTCTACAGAAGCTGGACAGAAACTGTTCAATATGCTGAGGCTT 1761
 Qy 561 GlyLysSerGluProTrpThrLeuAlaLeuGluAsnValValGlyValLysAsnMetAsn 580
 Db 1762 GGAANAATCAGAACCTTGACCTTAGCATTTGGAAATATGTTTAGGAGCAAAACATGAAT 1821
 Qy 581 ValArgProLeuLeuAsnTrpPheGluProLeuPheThrTrpLeuLysAspGlnAsnLys 600
 Db 1822 GTAAGGCCACTGTCTCAACTACTTTGAGCCCTTATTTACCTGGCTGAAAGACCCAGAACAG 1881
 Qy 601 AsnSerPheValGlyTrpSerThrAspTrpSerProTrpAlaAspGlnSerIleLysVal 620

Db 1882 AATCTTTTGGGATGGAGTACCGAGTCCATATGCAGACCAAGCATCAAAAGTG 1941
 QY 621 ArgTleSerLeuLysSerAlaLeuGlyAspLysAlaTyrGluTrpAsnAspAsnGluMet 640
 Db 1942 AGGATAGCTTAAATCAGCTCTTGGAGATAAAGCATATGAATGGACGACAAATGAATG 2001
 QY 641 TyrLeuPheArgSerSerValAlaTyrAlaMetArgGlnTyrPheLeuLysValLysAsn 660
 Db 2002 TACCTGTTCGCATCATCTGTTCATATGCTATGAGCGAGTACTTTTAAAAAGTAAAAAT 2061
 QY 661 GlnMetIleLeuPheGlyGluGluAspValArgValAlaLeuAsnLeuLysProArgIleSer 680
 Db 2062 CAGATGATCTTTTGGGGAGGAGATGTCGAGTGGCTTAATTTGAAACCAAGAAATCTCC 2121
 QY 681 PheAsnPheValThrAlaProLysAsnValSerAspIleIleProArgThrGluVal 700
 Db 2122 TTTTAAATTTCTTGTCACTGCACCTTAAATATGTCTGTGATATCATCTCTAGAACTGAAGTT 2181
 QY 701 GluLysAlaIleArgMetSerArgSerArgIleAsnAspAlaPheArgLeuAsnAspAsn 720
 Db 2182 GAAAGGCCATCAGGATGTCGAGGACCGTATCAATGATGCTTTCGCTCTCAATGACAC 2241
 QY 721 SerLeuGluPheLeuGlyIleGlnProThrLeuGlyProProAsnGlnProProValSer 740
 Db 2242 AGCCTAGAGTTCTGGGATACAGCCACACTTGGACCTCTCTAAACGACGCCCTGTTTCC 2301
 QY 741 IleTrpLeuIleValPheGlyValValMetGlyValIleValValGlyIleValIleLeu 760
 Db 2302 ATATGCTGATGTTTGTGGAGTTGTGATGGAGTGATAGTGTGGCATGTGATCTG 2361
 QY 761 IlePheThrGlyIleArgAspArgLysLysLysAsnLysAlaArgSerGlyGluAsnPro 780
 Db 2362 ATCTTCACTGGATCAGATCGAAGAGAAAGAAATAAAGCAAGAAAGTGGAGAAATCCT 2421
 QY 781 TyrAlaSerIleAspIleSerLysGlyGluAsnAsnProGlyPheGlnAsnThrAspAsp 800
 Db 2422 TATGCTCCATCGATATACCAAGGAGAAATAATCCAGGATTCCAAAACACTGATGAT 2481
 QY 801 ValGlnThrSerPhe 805
 Db 2482 GTTCAGACCTCCTTT 2496
 RESULT 5
 AAS21279
 ID AAS21279 standard; cDNA; 3732 BP.
 XX AC AAS21279;
 XX DT 24-OCT-2001 (first entry)
 XX DE Human cDNA sequence encoding for PRO1885 polypeptide.
 XX KW Human secretory and transmembrane; PRO; mammalian; cancer; lung;
 KW breast; prostate; cervical; tumour necrosis factor-alpha; TNF-alpha;
 KW cartilage; ear; proliferation; glucose; free fatty acid; skeletal muscle;
 KW adipocyte; A-peptide; factor VIIA; gene therapy; ss.
 OS Homo sapiens.
 XX PN WO200140466-A2.
 XX PD 07-JUN-2001.
 XX PF 01-DEC-2000; 2000WO-US32678.
 XX PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 02-DEC-1999; 99WO-US28551.
 PR 02-DEC-1999; 99WO-US28564.
 PR 02-DEC-1999; 99WO-US28565.
 PR 09-DEC-1999; 99US-0170262.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.

PR 20-DEC-1999; 99WO-US30999.
 PR 30-DEC-1999; 99WO-US31243.
 PR 06-JAN-2000; 2000WO-US00277.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 18-FEB-2000; 2000WO-US04342.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 01-MAR-2000; 2000WO-US05601.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 21-MAR-2000; 2000WO-US07532.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 10-NOV-2000; 2000WO-US30873.
 XX (GETH) GENENTECH INC.
 PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;
 XX WPI: 2001-408281/43.
 DR P-PSDB; AAI12207.
 XX
 PT Isolated, secretory and transmembrane PRO polypeptide used to detect
 other PRO polypeptides, link bioactive molecules to cells expressing
 PRO polypeptides, and detect the presence of mammalian tumours e.g.
 PT lung, breast, prostate, cervical
 PT
 XX
 PS Claim 3; Fig 71; 813pp; English.
 XX
 CC AAS21244-AAS21518 encode for novel human secretory and transmembrane
 PRO polypeptides. The PRO polypeptides are useful to detect other
 PRO polypeptides, to link bioactive molecules to cells expressing
 CC PRO polypeptides, to modulate biological activities of cells expressing
 CC PRO polypeptides, and to detect the presence of mammalian lung, colon,
 CC breast, prostate, rectal, cervical or liver tumours by comparing PRO
 CC polypeptide expression in a cell sample to that in a control sample.
 CC Some of the 275 sequences are also useful to stimulate the release of
 CC tumour necrosis factor-alpha (TNF-alpha) from human blood, the
 CC proliferation or differentiation of chondrocytes, the proliferation or
 CC gene expression in pericyte cells, the release of proteoglycans from
 CC cartilage, the proliferation of inner ear utricular supporting cells or
 CC of T-lymphocytes, the release of a cytokine from peripheral blood
 CC monocytes (PBMCs), or the proliferation of endothelial cells. Some of
 CC the PRO polypeptides may modulate glucose or free fatty acid uptake by
 CC skeletal muscle cells or by adipocytes; or inhibit binding of A-peptide
 CC to factor VIIA. The PRO polypeptides can be used in assays to identify
 CC molecules involved in binding interactions. The polynucleotides encoding
 CC PRO polypeptides can be used to generate probes, antisense RNA/DNA,
 CC transgenic or knock out animals and can be used in gene therapy.
 XX
 SQ Sequence 3732 BP; 1137 A; 722 C; 821 G; 1052 T; 0 other;

Alignment Scores:
 Pred. No.: 0 Length: 3732
 Score: 4142.00 Matches: 802
 Percent Similarity: 85.33% Conservative: 1
 Best Local Similarity: 85.23% Mismatches: 2
 Query Match: 96.53% Indels: 138
 DB: 22 Gaps: 1
 US-09-635-501-2 (1-805) x AAS21279 (1-3732)

QY 1 MetSerSerSerTrpLeuLeuSerLeuValAlaValThrAlaAlaGlnSerThr 20
 Db 40 ATGTCAAGCTCTCTCGCTCTTCTCAGCCTGTTGTTGTTACTGCTGCTCAGTCCACC 99

Qy 21 IleGluGluGlnAlaLysThrPheLeuAspLysPheAsnHisGluAlaGluAspLeuPhe 40
 Db 100 ATTGAGAACAGCCCAAGACATTTTGGACAAAGTTTAACCAAGCCGGAAGACCTGTTC 159
 Qy 41 TyrGlnSerSerLeuAlaSerTrpAsnTrpAsnThrAsnIleThrGluGluAsnValGln 60
 Db 160 TATCAAAGTTCACCTGCTTCTTGGAAATTAACACCAATATTAAGAGAAATGTCCAA 219
 Qy 61 AsnMetAsnAlaGlyAspLysTrpSerAlaPheLeuLysGluGlnSerThrLeuAla 80
 Db 220 AACATAAATGCTGGGACAAATGGTCTGCCTTTTAAAGGAACACAGTCACACTGGC 279
 Qy 81 GlnMetYrProLeuGlnGluIleGlnAsnLeuThrValLysLeuGlnLeuGlnAlaLeu 100
 Db 280 CAATGATCCACTACAAGAAATTCAGAAATCTCACAGTCAAGCTTCAAGCTGAGGCTCTT 339
 Qy 101 GlnGlnAsnGlySerSerValLeuSerGluAspLysSerLysArgLeuLeuAsnThrIleLeu 120
 Db 340 CAGCAAAATGGGTCTTCAAGTCTCTCAGAAAGACAGCAACCGTTGAACACAATCTA 399
 Qy 121 AsnThrMetSerThrIleYrSerThrGlyLysValCysAsnProAspAsnProGlnGlu 140
 Db 400 AATACAATGAGCACCATCTACAGTACTGGAAGATTTGTAACCCAGATAATCCACAAGRA 459
 Qy 141 CysLeuLeuLeuGluProGlyLeuAsnGluMetAlaAsnSerLeuAspYrAsnGlu 160
 Db 460 TGCCTTATCTTGAACCAAGTTGAATGAATAATGCAACAGTTTAGACTACAATGAG 519
 Qy 161 ArgLeuTrpAlaTrpGlnSerTrpArgSerGluValGlyLysGlnLeuArgProLeuYr 180
 Db 520 AGSCTCGGCTTGGAAAGCTGGAGATCTGAGGTGCGAAGCAGCTGAGGCCATATAT 579
 Qy 181 GluGluYrValValLeuLysAsnGluMetAlaArgAlaAsnHisIstYrGluAspYrGly 200
 Db 580 GAAGAGTATGCTGCTTGAATAATGAGATGGCAAGACGAATAATATGAGGACTATGG 639
 Qy 201 AspYrTrpArgGlyAspYrGlnValAsnGlyValAspGlyYrAspYrSerArgGly 220
 Db 640 GATATGAGAGGAGACTATGAAGTAAATGGGTAGATGGCTATGACTACAGCCCGGC 699
 Qy 221 GlnLeuIleGluAspValGluHisThrPheGluGluIleLysProLeuYrGluHisLeu 240
 Db 700 CAGCTGATGAAGATGTGAACATACCTTTGAAGAGATTAACCAATATATGAACATCT 759
 Qy 241 HisAlaYrValArgAlaLysLeuMetAsnAlaYrProSerYrIleSerProIleGly 260
 Db 760 CATGCCATGTGAGGCCAAAGTTGATGATGCCATCTCTTATATACATCCCAATGGA 819
 Qy 261 CysLeuProAlaHisLeuLeuGlyAspMetTrpGlyArgPheThrAsnLeuYrSer 280
 Db 820 TGCCTCCCTGCTCAATTTGCTTGGTATATGTGGGTAGATTTTGGACAAATCTGTACTCT 879
 Qy 281 LeuThrValProPheGlyClnLysProAsnIleAspValThrAspAlaMetValAspGln 300
 Db 880 TTGCAGTTCCCTTTGGACAGAAACCAACATAGATGTACTGATGCAATGGTGGACAG 939
 Qy 301 AlaTrpAspAlaGlnArgIlePheLysGluAlaGluLysPheValSerValGlyLeu 320
 Db 940 GCCTGGATGCACAGAAATATCAAGAGAGCCGAGAGTCTTTGTATCTGTTGGTCTT 999
 Qy 321 ProAsnMetThrGlnGlyPheThrPgluAsnSerMetLeuThrAspProGlyAsnValGln 340
 Db 1000 CCTAATATGACTCAAGGATCTCGGAAATTTCCATGTCAAGCGCACCGAGAAATGTTCAG 1059
 Qy 341 LysAlaValCysHisProThrAlaTrpAspLeuGlyLysGlyAspPheArgIleLeuMet 360
 Db 1060 AAAGCAGTCTGCCATCCACAGCTGGGACCTGGGAGCGGCACTTCAGATCCCTATG 1119
 Qy 361 CysThrLysValThrMetAspPheLeuThrAlaHisHisGluMetGlyHisIleGln 380
 Db 1120 TGCACAAAGGTGACAAATGGACACTTCTGACAGCTCATCATGAGATGGGCAATCCAG 1179
 Qy 381 TyrAspMetAlaTyrAlaGlnProPheLeuLeuArgAsnGlyAlaAsnGluGlyPhe 400

Db 1180 TATGATATGCATATATCTGCACAAACCTTTCTGCTAAGAAATGGAGCTAATGAAGATTC 1239
 Qy 401 HisGluAlaValGlyGluIleMetSerLeuSerAlaAlaThrProLysHisLeuLysSer 420
 Db 1240 CATGAAGCTGTTGGGAAATCATGTCACTTTCTGCAGCCACACCTAAGCATTTAAATCC 1299
 Qy 421 IleGlyLeuLeuSerProAspPheGlnGluAspAsnGluThrGluIleAsnPheLeuLeu 440
 Db 1300 ATTGGTCTTCTGTCACCCGATTTTCAAGAGAGAAATGAACAGAAATAAATCTCTCTC 1359
 Qy 441 LysGlnAlaLeuThrIleValGlyThrLeuProPheThrTyrMetLeuGluLysTrpArg 460
 Db 1360 AAACAAGCACTACGATTTGGGACTCTGCCATTTACTTACATGTTAGAGAAAGTGAGG 1419
 Qy 461 TrpMetValPheLysGlyGluIleProLysAspGlnTrpMetLysLysTrpTrpGluMet 480
 Db 1420 TGGATGCTCTTTAAAGGGGAAATTTCCCAAGACCAAGTGGTGAAGAGTGGTGGAGATG 1479
 Qy 481 LysArgGluIleValGlyValValGluProValProHisAspGluThrTyrCysAspPro 500
 Db 1480 AAGCGAGATAGTTGGGTGGTGAACCTGTGCCCATGATGAACATACTGTGACCCC 1539
 Qy 501 AlaSerLeuPheHisValSerAsnAspYrSerPheIleArgYrYrThrArgThrLeu 520
 Db 1540 GCATCTCTGTTCCATCTTCTGATGATTAATCATTCATTCGATATACACAAGGACCTT 1599
 Qy 521 TyrGlnPheGlnPheGlnGluAlaLeuCysGlnAlaAlaLysHisGluGlyProLeuHis 540
 Db 1600 TACCAATTCAGTTTTCAGANGACCTTGTCAANGCGTAAACATGAAGGCCCTCTGCAC 1659
 Qy 541 LysCysAspLysSerAsnSerThrGluAlaGlyGlnLysLeuPhe 555
 Db 1660 AAATGTGACATCTCAAACTCTACAGAAGCTGCACAGAAACTGTT-GTAAGAAATACCTCA 1718
 Qy 555 ----- 555
 Db 1719 AAATGTTGAACCTCTCCTAGTATTCAGTATTAATCTCATTTCCATGCCTAGTTGTTGTTG 1778
 Qy 555 ----- 555
 Db 1779 ATTTCTTTGTTTAAAAAGAAAAATTTTATGGCTCAAAATGTCTCTATTTACAAACCAA 1838
 Qy 555 ----- 555
 Db 1839 CATTTAATTTGGTCAGACAGAACCTAGACCATAACAACAATTTGGGTGGGCCACCTCTT 1898
 Qy 555 ----- 555
 Db 1899 TTCTCCCTATCAATACTACAGCCCTCTCTCTCTGTAATTTGGAAGGAAGAGCGTTTAG 1958
 Qy 555 ----- 555
 Db 1959 GGTGGAATATATCTGTTAATATGCAATCTTTTCTTTATCTGCCAGAACCAATTTAGCCAA 2018
 Qy 555 ----- 555
 Db 2019 GTCAAGAGAGAAACCATAGATCATAGATGTAATAATATATCTACATCTGGAACCCCTCAA 2078
 Qy 556 ----- 556
 Db 2079 AAGGCCCTGAACCCCTTTTTTTGTTAGCAATATGCTGAGGCTTGGAAATATCAGAACCC 2138
 Qy 566 TrpThrLeuAlaLeuGluAsnValValGlyAlaLysAsnMetAsnValArgProLeuLeu 585
 Db 2139 TGGACCTAGCATTTGGAATTTGTTAGGAGC-AAGAACATGAATGTAAAGCCACTGCTC 2197
 Qy 586 AsnYrPheGlnProLeuPheThrTrpLeuLysAspGlnAsnLysAsnSerPheValGly 605
 Db 2198 AACTACTTTGAGCCCTTATTACTTGGTGAAGAGACCAAGAAATCTCTTTTGTGGGA 2257
 Qy 606 TrpSerThrAspTrpSerProYrAlaAsp-GlnSerIleLysValArgIleSerLeuLys 625

Db 2258 TGGAGTACCGACTGGAGTCCATATGCAGACCCCAAGCATCAAGTGGAGTAAAGCCTAAA 2317
 QY 625 sserAlalaLeuGlyAspLysAlaTyrGluTrpAsnAspAsnGluMetTyrLeuPheArgse 645
 Db 2318 ATCAGCTCTGGAGATAAGCATATGATGGAACGACATGAATGTACCTGTTCGGATC 2377
 QY 645 fserValalaTyrAlaMetArgGlnTyrPheLeuLysValLysAsnGlnMetIleLeuPh 665
 Db 2378 ATCTGTTGCATATCTATGAGGAGTACTTTTAAAGTAAATAATACAGATGATCTTTT 2437
 QY 665 eGlyGluGluAspValArgValAlaAsnLeuLysProArgIleSerPheAsnPhePheVa 685
 Db 2438 TGGGAGAGAGATGTGGAGTGGCTTAATTGAACCAAGATCTCCTTAATTTCTTTGT 2497
 QY 685 lThrAlaProLysAsnValSerAspIleIleProArgThrGluValGluLysAlaIleAr 705
 Db 2498 CACTGCACCTAAAATGTCTGATATCATCTCTAGAACTGAAGTTGAAAAGGCCATCAG 2557
 QY 705 gMetSerArgSerArgIleAsnAspAlaPheArgLeuAsnAspAsnSerLeuGluPheLe 725
 Db 2558 GATGTCCCGAGGCGTATCAATGATGCTTTCCTCTGGAATGACACACGCTAGAGTTCT 2617
 QY 725 uGlyIleGlnProThrLeuGlyProProAsnGlnProProValSerIleTyrLeuIleVa 745
 Db 2618 GGGGATACAGCCAACTGTGACCTCTTAACCAAGCCCTGTTCATATGGCTGATTGT 2677
 QY 745 lPheGlyValIleValMetGlyValIleValGlyIleValIleLeuIlePheThrGlyI 765
 Db 2678 TTTTGGAGTTGTATGGAGTGATGAGTGGTTCGATTCATCCGATTCACCTGGGAT 2737
 QY 765 eArgAspArgLysLysLysAsnLysAlaArgSerGlyGluAsnProTyrAlaSerIleAs 785
 Db 2738 CAGAGATCGGAAGAAAGAAATAAGCAAGAGTGGAGAAATCCTATGCTCCATCCGA 2797
 QY 785 pIleSerLysGlyGluAsnAsnProGlyPheGlnAsnThrAspAspValGlnThrSerPh 805
 Db 2798 TATTAGCAAGAGAGAAATATCCAGATTCCAAAACACTGATGATGTTCAGACCTCCTT 2857
 QY 805 e 805
 Db 2858 T 2858
 RESULT 6
 AAS14880
 ID AAS14880 standard; cDNA; 2920 BP.
 XX
 AC AAS14880;
 XX
 DT 20-DEC-2001 (first entry)
 XX
 DE Human cDNA encoding novel human protein NHP #1.
 XX
 KW Human: novel human protein; NHP; ss: antidiabetic; antirheumatic;
 KW antirheumatic; cytosolic; antidiabetic; antirheumatic; antirheumatic;
 KW neuroprotective; neurotrophic; antiparkinsonian;
 KW anti-human immunodeficiency virus; antiaesthetic; vasotropic; cardiac;
 KW hypotensive; anorectic; antinfertility; neuroleptic; anticonvulsant;
 KW antitumor; immunosuppressive; cerebroprotective; antimicrobial;
 KW antinflammatory; antibacterial; antipsoriatic; thyromimetic;
 KW immunomodulator; antiseborrheic; dermatological; vasoconstriction;
 KW gastrointestinal disorder; cardiovascular disorder; hypertension;
 KW coronary heart disease; arteriosclerosis; anorexia; obesity; bulimia;
 KW cachexia; male infertility; impotence; testicular cancer; lung tumour;
 KW hyperproliferative disorder; pulmonary system disorder;
 KW central nervous system disorder; bone disorder;
 KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;
 KW Huntington's disease; schizophrenia; mania; dementia; paranoia;
 KW panic disorder; learning disability; amyotrophic lateral sclerosis;
 KW psychosis; autism; sleep disorder; immune system disorder;
 KW Hashimoto's thyroiditis; musculo-skeletal system disorders;
 KW multiple sclerosis; ischaemic brain injury; stroke; infectious disease;
 KW diabetes mellitus; immunological disorder; asthma; AIDS;
 KW acquired immunodeficient syndrome; leukaemia; rheumatoid arthritis;

KW inflammatory bowel disease; sepsis; acne; psoriasis; lupus erythematosus;
 KW neural system disorder; respiratory disorder; olfactory disorder;
 KW wound healing; chromosome X.
 OS Homo sapiens.
 XX
 FH Key Location/Qualifiers
 CDS 213..2348
 FT /*tag= a
 FT /product= "NHP #1"
 FT /transl_except= (pos:867..869,aa:Xaa)
 FT /transl_except= (pos:930..932,aa:Xaa)
 FT /transl_except= (pos:1707..1709,aa:Xaa)
 FT /note= "Xaa= Any amino acid"
 XX
 PN W0200174896-Al.
 XX
 XX 11-OCT-2001.
 PD
 XX 02-APR-2001; 2001WO-US10542.
 PF
 XX 03-APR-2000; 2000US-194118P.
 PR 29-SEP-2000; 2000US-236384P.
 XX
 XX (HUMA-) HUMAN GENOME SCI INC.
 XX
 XX Moore PA, Ni J, Soppet DR, Coleman TA, Gentz RL, Endress GA;
 PI Li Y, Dillon PJ;
 XX
 DR WPI: 2001-626394/72.
 DR P-PSDB; AAU09092.
 XX
 PT New human proteins, useful for diagnosing, treating, preventing and/or
 PT prognosing disorders related to the proteins, including cardiovascular
 PT disorders, autoimmune disorders and reproductive disorders -
 XX
 XX Claim 1; Page 291-292; 318pp; English.
 PS
 CC The invention relates to novel human proteins (NHP) and the
 CC nucleic acids that encode them and antibodies raised against them.
 CC The proteins, antibodies and nucleic acids are useful in the diagnosis,
 CC prognosis, prevention and/or treatment of diseases and/or disorders
 CC involving vasoconstriction, gastrointestinal disorders, cardiovascular
 CC disorders (e.g. hypertension, erectile dysfunction, high blood pressure,
 CC coronary heart disease and arteriosclerosis), anorexia, obesity, bulimia,
 CC cachexia, disorders of small intestine, disorders of reproductive system
 CC (e.g. male infertility and/or impotence), testicular cancer, lung tumours
 CC and other hyperproliferative disorders, disorders of pulmonary system,
 CC central nervous system disorders, bone disorders, neurodegenerative
 CC diseases and behavioural disorders (e.g. Alzheimer's disease, Parkinson's
 CC disease, Huntington's disease, schizophrenia, mania, dementia, paranoia,
 CC panic disorder, learning disabilities, amyotrophic lateral sclerosis,
 CC psychoses, autism, sleep disorders), immune system disorders (e.g.
 CC Hashimoto's thyroiditis), renal and musculo-skeletal system disorders,
 CC central nervous system disorders (e.g. multiple sclerosis, ischaemic
 CC brain injury and/or stroke), infectious diseases, diabetes mellitus,
 CC immunological disorders (e.g. asthma, acquired immunodeficient syndrome
 CC (AIDS), leukaemia, rheumatoid arthritis, inflammatory bowel disease,
 CC sepsis, acne, psoriasis and lupus erythematosus), neural system
 CC disorders, respiratory disorders, olfactory disorders and wound
 CC healing. The present sequence encodes an NHP of the invention and
 CC is located on the X chromosome.
 SQ Sequence 2920 BP; 897 A; 568 C; 654 G; 788 T; 13 other;

Alignment Scores:
 Pred. No.: 0 Length: 2920
 Score: 4061.00 Matches: 763
 Percent Similarity: 99.35% Conservatives: 1
 Best Local Similarity: 99.22% Mismatches: 4
 Query Match: 94.64% Indels: 1
 DB: 22 Gaps: 0

US-09-635-501-2 (1-805) x AA514880 (1-2920)

Qy 3 SerSerSerTrpLeuLeuSerLeuValAlaValThrAlaAlaGlnSerThrIleGlu 22
 Db 35 AGCTCTTCCTGGCTCTCTCAGCCTTGTGCTGAACCTGCTCAGTCACCATTTGAG 94
 Qy 23 GluGlnAlaIleThrPheLeu-AspLysPheAsnHisGluAlaGluAspLeuPheTrpG1 42
 Db 95 GAACAGCCCAAGACATTTTGGGCAAGTTTAAACCACCAAGCCGAGACCTGTTCTATCA 154
 Qy 42 nSerSerLeuAlaSerTrpAsnTrpAsnThrAsnIleThrGluGluAsnValGlnAsnMe 62
 Db 155 AAGTTCACTTGCCTCTTGAATTAACACCAATATTACTGAAGAGATGTCCAAACAT 214
 Qy 62 tAsnAsnAlaGlyAspLysTrpSerAlaPheLeuLysGluGlnSerThrIleuAlaGlnMe 82
 Db 215 GAATAATGCTGGGCAAAATGCTGCTCTTTTAAAGGAACAGCTCCACACTTGCCCAAT 274
 Qy 82 tTrpProLeuGlnGluIleGlnAsnLeuThrValLysLeuGlnLeuGlnAlaLeuGlnG1 102
 Db 275 GTATCCACTACAAGAAATTCAGAACTCAGCTCAAGCTTCAGCTGCAGGCTCTTCAGCA 334
 Qy 102 nAsnGlySerSerValLeuSerGluAspLysSerLysArgLeuAsnThrIleLeuAsnTh 122
 Db 335 AAATGGGCTTTCAGTCTCTCAGAGACCAAGCAAGCGTTGAACACAAATTTCTAAATAC 394
 Qy 122 rMetSerThrIleTrpSerThrGlyLysValCysAsnProAspAsnProGlnGluCysLe 142
 Db 395 AATGAGCACCATCTACAGTACTGGAAGTTTGTAAACCCAGATTAATCCACAGAAATGCTT 454
 Qy 142 uLeuLeuGluProGlyLeuAsnGluIleMetAlaAsnSerLeuAspTrpAsnGluArgLe 162
 Db 455 ATTACTTTGAACACAGGTTTGAATGAATATATGGCAACAGCTTTAGACTACATGAGAGCT 514
 Qy 162 uTrpAlaTrpGluSerTrpArgSerGluValGlyLysGlnLeuArgProLeuTrpGluG1 182
 Db 515 CTGGCTTGGGAAGCTGGAGTCTGAGCTCGGCAAGCAGCTGAGGCCATTTATATGAAGA 574
 Qy 182 uTrpValValLeuLysAsnGluMetAlaArgAlaAsnHisTrpGluAspTrpGlyAspTy 202
 Db 575 GTATGTGCTCTTGAAAATGAGATGGCAAGAGCAAAATCATTTATGAGGACTATGGGATTA 634
 Qy 202 rTrpArgGlyAspTrpGluValAsnGlyValAspGlyTrpAspTrpSerArgGlyGlnLe 222
 Db 635 TTGGAGAGAGACTATGAAGTAAATGGGGTAGATGGCTATGACTACAGCCCGCCCAAGTT 694
 Qy 222 uIleGluAspValGluHISThrPheGluGluIleLysProLeuTrpGluHisLeuHisAl 242
 Db 695 GATTTGAAGATGTGGAACATACCTTTGAAGAGATTAAACCATTTATGAACATCTTCATGC 754
 Qy 242 aTrpValArgAlaLysLeuMetAsnAlaTrpProSerTrpIleSerProIleGlyCysLe 262
 Db 755 CTATGAGGCCAAAGTTGATGAATGCCATTCCTTCTATATCAGTCCAAATGGATGCCCT 814
 Qy 262 uProAlaHisLeuLeuGlyAspMetTrpGlyArgPheTrpThrAsnLeuTrpSerLeuTh 282
 Db 815 CCCTGCTCATTTGCTGGTGATATGGGGTAGATTTTGGCAAAATTTGTACNSTTTGAC 874
 Qy 282 rValProPheGlyGlnLysProAsnIleAspValThrAspAlaMetValAspGlnAlaTr 302
 Db 875 AGTTCCCTTTGGACAGAAACCAACATAGATGTTACTGATCAATGGTGGACCAAGCTG 934
 Qy 302 pAspAlaGlnArgIlePheLysGluAlaGluLysPhePheValSerValGlyLeuProAs 322
 Db 935 GGATGCACAGAGAAATTAACAGAGCCGAGAGTTCTTTGTATCTGTTGCTCTCTAA 994
 Qy 322 nMetThrGlnGlyPheTrpGluAsnSerMetLeuThrAspProGlyAsnValGlnLysAl 342
 Db 995 TATGACTCAAGGATTTCTGGGAAATTTCCATGCTAAACGGACCCAGGAAATGTTCAAGAAGC 1054
 Qy 342 aValCysHisProThrAlaTrpAspLeuGlyLysGlyAspPheArgIleLeuMetCysTh 362
 Db 1055 AGTCTGCATCCACAGCTTGGGACCTGGGGGAAGGCGGACTTCAGATCTTATGTGTCAC 1114

Qy 362 rLysValThrMetAspPheLeuThrAlaHisHisGluMetGlyHisIleGlnTrpAs 382
 Db 1115 AAGGTGACAATGGAGACTTCTCGACGCTCATCATGAGATGGGCATATCCAGTATGA 1174
 Qy 382 pMetAlaTrpAlaAlaGlnProPheLeuLeuArgAsnGlyAlaAsnGluGlyPheHisG1 402
 Db 1175 TATGGCATATGCTGCAACACTTTTCTGCTAAGAAATGAGCTAATGAAGATTTCCATGA 1234
 Qy 402 uAlaValGlyGluIleMetSerLeuSerAlaAlaThrProLysHisLeuLysSerIleG1 422
 Db 1235 AGCTGTTGGGAAATCATGTCTCTCGACGACACCTAAGCATTTAAATCCATTGG 1294
 Qy 422 yLeuLeuSerProAspPheGlnGluAspAsnGluThrGluIleAsnPheLeuLeuLysG1 442
 Db 1295 TCTTCTGTCAACCGATTTTCAAGAAGCAATGAACAGAAATAAACTTCTCGCTCAACA 1354
 Qy 442 nAlaLeuThrIleValGlyThrLeuProPheThrTrpMetLeuGluLysTrpArgTrpMe 462
 Db 1355 AGCACTCACGATTTGGGACTCTGCCATTTACTTACATGTTAGAGAAGTGGAGTGGAT 1414
 Qy 462 tValPheLysGlyGluIleProLysAspGlnTrpMetLysLysTrpTrpGluMetLysAr 482
 Db 1415 GGTCTTTAAAGGGGAAATTTCCCAAGACCAAGTGGATGAAAAAGTGGTGGAGATGAAGCG 1474
 Qy 482 gGluIleValGlyValValGluProValProHisAspGluThrTrpCysAspProAlaSe 502
 Db 1475 AGAGATAGTTGGGTGGTGAACCTCTGCCCATGATGAACATACTGTGACCCCGCATC 1534
 Qy 502 rLeuPheHisValSerAsnAspTrpSerPheIleArgTrpTrpThrArgThrLeuTrpG1 522
 Db 1535 TCTGTTCCATGTTTCTAATGATTTACTCATTTCTGATATTACACAGAGACCTTTTACCA 1594
 Qy 522 nPheGlnPheGlnGluAlaLeuCysGlnAlaLysHisGluGlyProLeuHisLysCy 542
 Db 1595 ATTCACGTTTCAAGAGCACTTTGTCAAGCAGCTAAACATGAAGCCCTCTGCACAAATG 1654
 Qy 542 sAspIleSerAsnSerThrGluAlaGlyGlnLysLeuPheAsnMetLeuArgLeuGlyLy 562
 Db 1655 TCACATCTCAAACTCTACAGAAGCTGGACAGAACTGTTTCAATATGCTGAGGNTTGGAAA 1714
 Qy 562 sSerGluProTrpThrLeuAlaLeuGluAsnValValGlyAlaLysAsnMetAsnValAr 582
 Db 1715 ATCAGAACCTTGGACCTTACCATTTGCAAAATGTTGTAGGAGCAAGACATGAATGAAG 1774
 Qy 582 gProLeuLeuAsnTrpPheGluProLeuPheThrTrpLeuLysAspGlnAsnLysAsnSe 602
 Db 1775 GCCACTGCTCAACTACTTTTGGCCCTTATTTACTGGCTGAAAGACCAAGCAAGAAATTC 1834
 Qy 602 rPheValGlyTrpSerThrAspTrpSerProTrpAlaAspGlnSerIleLysValArgI1 622
 Db 1835 TTTTGTGGGATGGAGTACCAGCTGGAGTCCATATGCGAGACCAAGCATCAAGTGGAGAT 1894
 Qy 622 eSerLeuLysSerAlaLeuGlyAspLysAlaTrpGluTrpAsnAspAsnGluMetTrpLe 642
 Db 1895 AAGCCTAAAAATCAGCTTGGAGATAAAGCATATGAATGGAACGACAATGAAATGTACCT 1954
 Qy 642 uPheArgSerSerValAlaTrpAlaMetArgGlnTrpPheLeuLysValLysAsnGlnMe 662
 Db 1955 GTTCCGATCATCTGTTGCATATGCTATGAGGCAGTACTTTTTTAAAGTAAATAATCAGAT 2014
 Qy 662 tIleLeuPheGlyGluGluAspValArgValAlaAsnLeuLysProArgIleSerPheAs 682
 Db 2015 GATTTCTTTTGGGAGGAGGATGTGCGAGTGGCTAATTTGAAACCAAGAAATCTCCTTTAA 2074
 Qy 682 nPhePheValThrAlaProLysAsnValSerAspIleIleProArgThrGluValGluLy 702
 Db 2075 TTTCTTTGTCACGTGACCTAAAAATGTGCTGATATCATTTCTAGACTGAAGTTGAAAA 2134
 Qy 702 sAlaIleArgMetSerArgSerArgIleAsnAspAlaPheArgLeuAsnAspAsnSerLe 722
 Db 2135 GGCCATCAGGATGTCCCGGAGCGGTATCAATGATGCTTCCGTCTGAATGACGAGCGCT 2194

Oy 722 uGluPheLeuGlyIleGlnProThrLeuGlyProProAsnGlnProProValSerIleTr 742
 Db 2195 AGAGTTTCTGGGATACAGCAACACTTGGACCTCTAACCCAGCCCTGTTCATATG 2254

Oy 742 pleuIleValPheGlyValValMetGlyValIleValValGlyIleValIleLeuIlePh 762
 Db 2255 GGTAGTGTCTTGGAGTTGTGATGGAGGTGATAGTGGTGGCATGTGCATCTGTGATCTT 2314

Oy 762 eThrGlyIleArgAspArgLysLys 770
 Db 2315 CACTGGCATCAGATCGGAAGAAG 2339

RESULT 7
 AAS14890
 ID AAS14890 standard; cDNA; 2911 BP.
 AC AAS14890;
 XX
 XX
 DT 20-DEC-2001 (first entry)
 XX Human cDNA encoding novel human protein NHP #11.
 DE Human; novel human protein; NHP; ss; antidiabetic; antirheumatic;
 KW antiarthritic; cytostatic; antiarteriosclerotic; vulnery;
 KW neuroprotective; nootropic; antiparkinsonian;
 KW anti-human immunodeficiency virus; antiasthmatic; vasotropic; cardiant;
 KW hypotensive; anorectic; antinfertility; neuroleptic; anticonvulsant;
 KW antitmanic; immunosuppressive; cerebroprotective; antimicrobial;
 KW antiinflammatory; antibacterial; antipsoiatric; thyromimetic;
 KW immunomodulator; antiseborrheic; dermatological; vasoconstriction;
 KW gastrointestinal disorder; cardiovascular disorder; hypertension;
 KW coronary heart disease; arteriosclerosis; anorexia; obesity; bulimia;
 KW cachexia; male infertility; impotence; testicular cancer; lung tumour;
 KW hyperproliferative disorder; pulmonary system disorder;
 KW central nervous system disorder; bone disorder;
 KW neurodegenerative disease; Alzheimer's disease; Parkinson's disease;
 KW Huntington's disease; schizophrenia; mania; dementia; paranoia;
 KW panic disorder; learning disability; immune system disorder;
 KW psychosis; autism; sleep disorder; immunodeficient syndrome;
 KW Hashimoto's thyroiditis; musculo-skeletal system disorders;
 KW multiple sclerosis; ischemic brain injury; stroke; infectious disease;
 KW diabetes mellitus; immunological disorder; asthma; AIDS;
 KW acquired immunodeficient syndrome; leukaemia; rheumatoid arthritis;
 KW inflammatory bowel disease; sepsis; acne; psoriasis; lupus erythematosus;
 KW neural system disorder; respiratory disorder; olfactory disorder;
 KW wound healing.
 XX Homo sapiens.

OS
 XX Key Location/Qualifiers
 FH 213..998
 FT CDS /*tag= a
 FT /*product= "NHP #11"
 FT
 XX WO200174896-A1.
 XX
 XX 11-OCT-2001.
 XX
 XX 02-APR-2001; 2001WO-US10542.
 XX
 XX 03-APR-2000; 2000US-194118P.
 PR 29-SEP-2000; 2000US-236384P.
 PR
 XX (HUMA-) HUMAN GENOME SCI INC.
 PA
 PI Moore PA, NI J, Soppet DR, Coleman TA, Gentz RL, Endress GA;
 PI Li Y, Dillon RJ;
 XX
 XX WPL: 2001-626394/72.
 DR P-PSDB; RAU09102.
 DR
 XX New human proteins, useful for diagnosing, treating, preventing and/or
 PT prognosing disorders related to the proteins, including cardiovascular

PT disorders, autoimmune disorders and reproductive disorders -
 XX Claim 1; Page 297-298; 318pp; English.
 XX
 CC The invention relates to novel human proteins (NHP) and the
 CC nucleic acids that encode them and antibodies raised against them.
 CC The proteins, antibodies and nucleic acids are useful in the diagnosis,
 CC prognosis, prevention and/or treatment of diseases and/or disorders
 CC involving vasoconstriction, gastrointestinal disorders, cardiovascular
 CC disorders (e.g. hypertension, erectile dysfunction, high blood pressure,
 CC coronary heart disease and arteriosclerosis), anorexia, obesity, bulimia,
 CC cachexia, disorders of small intestine, disorders of reproductive system
 CC (e.g. male infertility and/or impotence), testicular cancer, lung tumours
 CC and other hyperproliferative disorders, disorders of pulmonary system,
 CC central nervous system disorders, bone disorders, neurodegenerative
 CC diseases and behavioural disorders (e.g. Alzheimer's disease, Parkinson's
 CC disease, Huntington's disease, schizophrenia, mania, dementia, paranoia,
 CC panic disorder, learning disabilities, amyotrophic lateral sclerosis,
 CC psychoses, autism, sleep disorders), immune system disorders (e.g.
 CC Hashimoto's thyroiditis), renal and musculo-skeletal system disorders,
 CC central nervous system disorders (e.g. multiple sclerosis, ischaemic
 CC brain injury and/or stroke), infectious diseases, diabetes mellitus,
 CC immunological disorders (e.g. asthma, acquired immunodeficient syndrome
 CC (AIDS), leukaemia, rheumatoid arthritis, inflammatory bowel disease,
 CC sepsis, acne, psoriasis and lupus erythematosus), neural system
 CC disorders, respiratory disorders, olfactory disorders and wound
 CC healing. The present sequence encodes an NHP of the invention.
 XX
 SQ Sequence 2911 BP; 896 A; 570 C; 655 G; 788 T; 2 other;
 Alignment Scores:
 Pred. No.: 0 Length: 2911
 Score: 4013.00 Matches: 763
 Percent Similarity: 99.35% Conservative: 1
 Best Local Similarity: 99.22% Mismatches: 4
 Query Match: 93.52% Indels: 3
 DB: 22 Gaps: 0

US-09-635-501-2 (1-805) x AAS14890 (1-2911)

Oy 3 SerSerTrpLeuLeuSerLeuValAlaValThrAlaAlaGlnSerThrIleGlu 22
 Db 35 AGCTTCTCTGGCTCTCTCTCAGCCTTGTGTCTGTAACCTGCTCAGTCCACCATGAG 94

Oy 23 GluGlnAlaLysThrPheLeu-AspLysPheAsnHisGluAlaGluAspLeuPheTyG1 42
 Db 95 GACAGGCCAAGACATTTTGGGACAAAGTTTACCCAGGAGCGAAGACCTGTCTTATCA 154

Oy 42 nSerSerLeuAlaSerTrpAsnTrpAsnThrAsnIleThrGluGluAsnValGlnAsnMe 62
 Db 155 AAGTTCACTTCTTCTTGGAAATTATACACCAATATTACTGAAGAGAATGTCCAAACAT 214

Oy 62 tAsnAsnAlaGlyAspLysTrpSerAlaPheLeuLysGluGlnSerThrLeuAlaGlnMe 82
 Db 215 GAATAATGCTGGGACAAATGGTCTGCTCTTTTAAAGGAACAGTCCACACTGTCCCAAT 274

Oy 82 tTyrProLeuGlnGluIleGlnAsnLeuThrValLysLeuGlnAlaLeuGlnI 102
 Db 275 GTATCCACTACAAGAAATTCAGAAATCTCAGATCAAGTTCAGCTCAGGCTCTTCAGCA 334

Oy 102 tAsnGlySerValLeuSerGluAspLysSerLysArgLeuAsnThrIleLeuAsnTh 122
 Db 335 AAATGGGTCTTCAGTGGCTCTCAGGAACAAGCAACGGTTGAACCAATTTCTTAATAC 394

Oy 122 tMetSerThrIleTyrSerThrGlyLysValCysAsnProAspAsnProGlnGluCysLe 142
 Db 395 AATGAGCACCATCTACAGTACTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 454

Oy 142 uLeuLeuGluProGlyLeuAsnGluIleMetAlaAsnSerLeuAspTyrAsnGluArdle 162
 Db 455 ATTACTTGAACACAGGTGTGAATGAATAATGCGCAACAGTTTAGACTACATGAGAGGCT 514

Oy 162 uTrpAlaTrpGluSerTrpArgSerGluValGlyLysGlnLeuArgProLeuTyrGluI 182

515 CTGGCTTGGGAAAGCTGAGATCTGAGGTGGCAAGCAGCTGAGGCCATATATGAAGA 574
 182 uTyValValLeuLysAsnGluMetAlaArgAlaAsnHisTyTyrGluAspTyrGlyAspTy 202
 575 GTATGTGGTCTTGAATAATGAGATGGCAAGAGCAAAATCAATTATGAGGACTATGGGATTA 634
 202 rTTPArgGlyAspTyrGluValAsnGlyValAspGlyTyrAspTyrSerArgGlyGlnLe 222
 635 TTGGAGGAGGAGACTATGAAGTAATAATGGGTAGATGGGTATGACTACAGCGCGGCCAGTT 694
 222 uileGluAspValGluHisThrPheGluGluIleLysProLeuTyrGluHisLeuHisAl 242
 695 GATTGAAGATGTGGAACATACCTTTGAAGAGATTAACACCATATATGAACATCTTCATGC 754
 242 aTyValArgAlaLysLeuMetAsnAlaTyrProSerTyrIleSerProIleGlyCyste 262
 755 CTATGTGAGGCCAAATTTGATGAATGCTATCTCTTCATATCAGTCCAAATGGATGGCT 814
 262 uProAlaHisLeuLeuGlyAspMetTTPGlyArgPheThrAsnLeuTyrSerLeuth 282
 815 CCTGTCTCATTTGCTTGGTGATATGCTGGGTAGATTTGGACAAATCTGTACTCTTTGAC 874
 282 rValProPheGlyGlnLysProAsnIleAspValThrAspAlaMetValAspGlnAlaTr 302
 875 AGTTCCCTTTGGACAGAAACCAACATAGATGTTACTGATGCAATGGTGGACCGAGCTG 934
 302 pAspAlaGlnArgIlePheLysGluAlaGluLysPhePheValSerValGlyLeuProAs 322
 935 GGATGCACAGAGAAATATCAAGAGCGCGGAGAGTCTT-GTATCTTGGTCTTCTCTAA 993
 322 nMetThrGlnGlyPheTrpGluAsnSerMetLeuThrAspProGlyAsnValGlnLysAl 342
 994 TATGACTCAAGGATTCCTGGGAAATTCCTCAATGCAAGGACCCAGGAAATGTTCCAGAAAG 1053
 342 aValCysHisProThrAlaTrpAspLeuGlyLysGlyAspPheArgIleLeuMetCysTh 362
 1054 AGTCTCCATGCCACAGCTTGGGAGCTGGGGAAGGGGAGCTTCAGGATCTTATGTGAC 1113
 362 rLysValThrMetAspAspPheLeuThrAlaHisGluMetGlyHisIleGlnTyrAs 382
 1114 AAAGGTGACAATGGAGCATTCTCACAGCTCATCATGAGATGGGCATATCCAGTATGA 1173
 382 pMetAlaTyrAlaAlaGlnProPheLeuLeuArgAsnGlyAlaAsnGluGlyPheHisGl 402
 1174 TATGGCATATGTGCAACACCTTTCTGCTAAGAAATGGAGCTAATGAAGGATTCATGA 1233
 402 uAlaValGlyGluIleMetSerLeuSerAlaAlaThrProLysHisLeuLysSerIleGl 422
 1234 AGCTGTGGGAAATCATGCTACTTCTGACGACACACCTPAAGCATTTAAATCCATGG 1293
 422 YLeuLeuSerProAspPheGlnGluAspAsnGluThrGluIleAsnPheLeuLeuLysGl 442
 1294 TCTTCTGTCCCGGATTTTCAAGAGAGCAATGAACAGAAATAAATCTCTGCTCAACAA 1353
 442 nAlaLeuThrIleValGlyThrLeuProPheThrTyrMetLeuGluLysTrpArgTrpMe 462
 1354 AGCACTCAGATGTTGGGACTCTCCCATTTACTTACATGTTAGAGAGTGGAGGTGGAT 1413
 462 tValPheLysGlyGluIleProLysAspGlnTrpMetLysLysTrpTrpGluMetLysAr 482
 1414 GGTCTTTAAAGGGGAAATTTCCCAAGAGACAGTGGATGAAGAAAGTGGTGGGAGATGAAGCG 1473
 482 gGluIleValGlyValValGluProValProHisGluThrTyrCysAspProAlaSe 502
 1474 AGAGATAGTGGGGTGGTGGAACTTGTGCCCATGATGAACATACTGTGACCCCGCATC 1533
 502 rLeuPheHisValSerAsnAspTyrSerPheIleArgTyrTyrThrArgThrLeuTyrGl 522
 1534 TCTGTTCCATGTTCTTAATGATTACTTATTCATTCATATACACAGGACCCCTTTACCA 1593
 522 nPheGlnPheGlnGluAlaLeuLysGlnAlaLysHisGluGlyProLeuHisLysCy 542

1594 ATTCCAGTTTCAAGAGAGCAGCTTTGTCAAGCAGCTAAACATGAAGGCCCTCTGCACAAATG 1653
 542 sAspIleSerAsnSerThrGluAlaGlyGlnLysLeuPheAsnMetLeuArgLeuGlyLys 562
 1654 TGACATCTC-AACTCTACAGAAAGCTGGACAGAAACTGTTCATATGCTGAGGNTTGGAAA 1712
 562 sSerGluProTrpThrLeuAlaLeuGluAsnValValGlyAlaLysAsnMetAsnValAr 582
 1713 ATCAGAACCTTGAGCCCTAGCATTTGAAATGTTGTAGAGCAAGAACATGAATGTAG 1772
 582 gProLeuLeuAsnTyrPheGluProLeuPheThrTrpLeuLysAspGlnAsnLysAsnSe 602
 1773 GCCACTGCTCAACTACTTTTGGCCCTTATTTACCTGGCTGAAAGACCAAGCAAGAAATTC 1832
 602 rPheValGlyTrpSerThrAspTrpSerProTyrAlaAspGlnSerIleLysValArgIle 622
 1833 TTTTGGGATGGAGTACCGACTGGAGTCCATATCAGACCAAGCATCAAGTGAAGAT 1892
 622 eSerLeuLysSerAlaLeuGlyAspLysAlaTyrGluTrpAsnAspAsnGluMetTyrLe 642
 1893 AAGCTTAAATCAGCTCTTGGAGATTAAGCATATCAATGGAACGACATGAATGTACCT 1952
 642 uPheArgSerSerValAlaTyrAlaMetArgGlnTyrPheLeuLysValLysAsnGlnMe 662
 1953 GTTCCGATCATCTGTTGCATATGCTATGAGGAGTACTTTTTTAAAGGTAAATAATCAGAT 2012
 662 tIleLeuPheGlyGluGluAspValArgValAlaAsnLeuLysProArgIleSerPheAs 682
 2013 GATCTTTTGGGAGAGGATGTCGGAGTGGCTAATTTGAAACCAAGATCTCTTTAA 2072
 682 nPhePheValThrAlaProLysAsnValSerAspIleIleProArgThrGluValGluLys 702
 2073 TTTCTTTGCTCACTGCACCTTAAATAATGCTGCTGATATCATCTAGAACTGAAGTTGAAA 2132
 702 sAlaIleArgMetSerArgSerArgIleAsnAspAlaPheArgLeuAsnAspSerLe 722
 2133 GCCATCAGATGTCGGGAGCGGTATCAATGCTTTCCGCTCTGATGACGACACCT 2192
 722 uGluPheLeuGlyIleGlnProThrLeuGlyProProAsnGlnProProValSerIleTr 742
 2193 AGATTCTGGGATACAGCAACACTTGGACTCTCTAACAGGCCCTGTGTTCCATATG 2252
 742 pLeuIleValPheGlyValValMetGlyValIleValValGlyIleValIleLeuIlePh 762
 2253 GCTGATTGTTTTGGAGTTGTGATGGAGTGTAGTGTGGTGTGATCTGATCTCTGATCTT 2312
 762 eThrGlyIleArgAspArgLysLys 770
 2313 CACTGGGATCAGAGATCGGAAGAAG 2337
 RESULT 8
 AAZ59466
 ID AAZ59466 standard; DNA; 2262 BP.
 XX AC AAZ59466;
 XX AC
 XX XX
 XX 11-APR-2000 (first entry)
 XX Human MPROT15 coding sequence #2.
 DE
 XX MPROT15; treatment; hypertension; human; myocardial disease; apoplexy;
 KW heart disease; apoplexy; heart disease; nervous denaturation; ds;
 KW Alzheimer's disease; hormone; cytokine.
 XX Homo sapiens.
 OS
 FN JPI1318472-A.
 XX
 XX 24-NOV-1999.
 XX
 XX 22-JAN-1999; 99JP-0014949.
 XX
 XX 13-MAY-1998; 98GB-0010373.
 PR

PR 18-AUG-1998: 98GB-0018009.

XX (SMIK) SMITHKLINE BEECHAM PLC.

XX WPI: 2000-109268/10.

XX MPROT15 polypeptide and MPROT15 polynucleotides - useful for the
PT treatment of hypertension, myocardial diseases, apoplexy, heart
PT diseases, nervous denaturation, Alzheimer's disease etc.

XX Claim 18; Page 15; 22pp; Japanese.

XX This is coding sequence #2 of human MPROT15. The MPROT15 polynucleotide
CC and polypeptide sequences can be used for the treatment of hypertension,
CC myocardial diseases, apoplexy, heart diseases, nervous denaturation,
CC Alzheimer's disease and diseases related to the processing of peptide
CC hormones and cytokines.

XX Sequence 2262 BP; 693 A; 450 C; 523 G; 596 T; 0 other;

Alignment Scores:

Pred. No.:	0	Length:	2262
Score:	3740.50	Matches:	711
Percent Similarity:	90.57%	Conservative:	9
Best Local Similarity:	89.43%	Mismatches:	12
Query Match:	87.17%	Indels:	63
DB:	21	Gaps:	3

US-09-635-501-2 (1-805) x AA259466 (1-2262)

QY 11 LeuValAlaValThrAlaAlaGlnSerThrIleGluGluGlnAlaLysThrPheLeuAsp 30
DB 64 CTTCTTCTTAACCTGCTCAAGTCCACCATTTGAGAACAGGCCAAGACATTTTGGAC 123
QY 31 LysPheAsnHisGluAlaGluAspLeuPheTyrglnSerSerLeuAlaSerTrpAsnTyr 50
DB 124 AAGTTTAAACCAAGCCGAGACCTGTTCTATCAAGTTCACTGCTCTTGGAAATAT 183
QY 51 AsnThrAsnIleThrGluGluAsnValGlnAsnMetAsnAsnAlaGlyAspLysTrpSer 70
DB 184 AACACCAATATTACTGAAGAGATGTCCAAACATGAATATGCTGGGCAAAATGGTCT 243
QY 71 AlaPheLeuLysGluGlnSerThrLeuAlaGlnMetTyrglnGlnIleGlnAsn 90
DB 244 GCCTTTTAAAGGAACAGTCCACACTTGCCTCAAAATGATCCACTACAGAATTCAGAT 303
QY 91 LeuThrValLysLeuGlnGlnAlaLeuGlnGlnAsnGlySerSerValLeuSerGlu 110
DB 304 CTCACAGTCAAGCTTCAGCTGCAGGCTCTTCAGCAAAATGGGCTCTCAGTCTCAGAA 363
QY 111 AspLysSerLysArgLeuAsnThrIleLeuAsnThrMetSerThrIleTyrglnGly 130
DB 364 GACAAGAGCAACGGTTGAACACAAATCTTAATACAAAGAGCACCATCTACAGTACTGGA 423
QY 131 LysValCysAsnProAspAsnProGlnGluCysLeuLeuLeuGluProGlyLeuAsnGlu 150
DB 424 AAAGTTTGTAAACCCAGATAATCCACAAGAATGCTTATTACTTGAACCAAGTTTGAATGAA 483
QY 151 IleMetAlaAsnSerLeuAspTyrglnGluArgLeuTrpAlaTrpGluSerTrpArgSer 170
DB 484 ATAATGGCAACAGTTTAGACTACAATAGAGGCTCTGGGCTTGGGAAGCTGGAGATCT 543
QY 171 GluValGlyLysGlnLeuArgProLeuTyrglnGluTyrglnValValLeuLysAsnGluMet 190
DB 544 GAGTCCGCAAGCAGCTGAGGCCATTATATGAAGAGTATGTGGTCTTGAAAAATGAGATG 603
QY 191 AlaArgAlaAsnHisTyrglnAspTyrglnAspTyrglnArgGlyAspTyrglnValAsn 210
DB 604 GCAAGACCAATCATTTAGGACTATGGGATTTATGGAGAGGAGACTATCAAGTAAAT 663
QY 211 GlyValAspGlyTyrglnAspTyrglnArgGlyGlnLeuIleGluAspValIleHisThrPhe 230
DB 664 GGGGTAGATGGCTATGACTACAGCCGCGCCAGTGTGATGAAGATGTGGAACATACCTTT 723

QY 231 GluGluIleLysProLeuTyrglnHisLeuHisAlaTyrglnAlaLysLeuMetAsn 250
DB 724 GAAGAGATTAAACCATTTATGAACATCTTCATGCTCTGTGAGGCAAACTTGATGAAT 783
QY 251 AlaTyrglnProSerTyrglnSerProIleGlyCysLeuProAlaHisLeuGlyAspMet 270
DB 784 GCCATCTCTTATATACAGTCCAAATGGATGCTCCCTGCTCATTTGCTTGGTGAATG 843
QY 271 TrpGlyArgPheThrAsnLeuTyrglnSerLeuThrValProPheGlyGlnLysProAsn 290
DB 844 TGGGTAGATTGGACAAATCTGTACTCTTTCACAGTTCCCTTGGACAGAAACAAAC 903
QY 291 IleAspValThrAspAlaMetValaspGlnAlaTrpAspAlaGlnArgIlePheLysGlu 310
DB 904 ATAGATGTTACTGATGCAATGGTGGACCGAGGCTGGGATGCACAGAGATATTCAAGAG 963
QY 311 AlaGluLysPhePheValSerValGlyLeuProAsnMetThrGlnGlyPheTrpGluAsn 330
DB 964 GCCGAGAAGTTCTTTGTATCTGTGGTCTTCCCTAATATGACTCAAGGATTTCTGGAAAT 1023
QY 331 SerMetLeuThrAspProGlyAsnValGlnLysAlaValCysHisProThrAlaTrpAsp 350
DB 1024 TCCATGCTAACGACCCAGGAATGTTCAAGAACAGTCTGCCATCCACAGCTTGGGAC 1083
QY 351 LeuGlyLysGlyAspPheArgIleLeuMetCysThrLysValThrMetAspAspPheLeu 370
DB 1084 CTGGGAAGGCGGACTTCAGGATCTTATGTGCACAAAGCTGACAATGGACGACTCCTG 1143
QY 371 ThrAlaHisHisGluMetGlyHisIleGlnTyrglnAspMetAlaTyrglnAlaGlnProPhe 390
DB 1144 ACAGCTCATATGAGATGGGCGATATCCAGTATGATATGCTATGCTGCACAACTTTT 1203
QY 391 LeuLeuArgAsnGlyAlaAsnGluGlyPheHisGluAlaValGlyIleMetSerLeu 410
DB 1204 CTGCTAAGAAATGGAGCTAATGAAGGATTCATGAAGCTGTTGGGGAATCATGTCATT 1263
QY 411 SerAlaAlaThrProLysHisLeuLysSerIleGlyLeuLeuSerProAspPheGlnGlu 430
DB 1264 TCTGACGCCACACTTAAGCATTTAAATCCATTTGGTCTTGTCTCACCCTGATTTTCAGAA 1323
QY 431 AspAsnGluThrGluIleAsnPheLeuLeuLysGlnAlaLeuThrIleValGlyThrLeu 450
DB 1324 GACAATGAACAGAAATAAATCTCCTGCTCAAAACAGCACTCACGATTTGTTGGGACTCTG 1383
QY 451 ProPheThrTyrglnMetLeuGluLysTrpArgTrpMetValPheLysGlyIleProLys 470
DB 1384 CCATTTACTTACATGTTAGAGAAAGTGGAGTGGTGGTCTTTAAAGGGGAAATCCCCAA 1443
QY 471 AspGlnTrpMetLysLysTyrglnGluMetLysArgGluIleValGlyValGluPro 490
DB 1444 GACCAGTGGATGAANAAGTGGTGGGAGATGAA----- 1476
QY 491 ValProHisAspGluThrTyrglnCysAspProAlaSerLeuPheHisValSerAsnAspTyr 510
DB 1476 ----- 1476
QY 511 SerPheIleArgTyrglnThrArgThrLeuTyrglnPheGlnPheGlnGluAlaLeucys 530
DB 1477 -----TATTACACAAGACCCCTTTACCAATTTCCAGTTTCAAGAGCATTGTT 1524
QY 531 GlnAlaLysHisGluGlyProLeuHisLysCysAspIleSerAsnSerThrGluAla 550
DB 1525 CAAGCAGCTAAACATGAAGCCCTCTGCACAAATGTGACATCTCAAACTCTACAGAAGCT 1584
QY 551 GlyGlnLysLeuPheAsnMetLeuArgLeuGlyLysSerGluProTrpThrLeuAlaLeu 570
DB 1585 GGACAGAAACGTTCATATGCTGAGCTTGGAAAATCAGAAACCTTGACCCCTGACATTG 1644
QY 571 GluAsnValValGlyAlaLysAsnMetAsnValArgProLeuLeuAsnTyrglnPheGluPro 590
DB 1645 GAAATGTTGTAGGAGCAAGAACATGAATGTAAAGCCACTGCTCAACTACTTTGAGCCC 1704

```
QY 591 LeuPheThrTrpLeuLysAspGlnAsnLysAsnSerPheValGlyTrpSerThrAspTrp 610
|||||
Db 1705 TTATTACCTGGCTGAAGACCAACAGAAATCTTTTGGGATGGAGTACCGACTGG 1764
QY 611 SerProTyrAlaAspGlnSerIleLysValArgIleSerLeuLysSerAlaLeuGlyAsp 630
|||||
Db 1765 AGTCCATGG----- 1773
QY 631 LysAlaTyrGluTrpAsnAspGluMetTyrLeuPheArgSerSerValAlaTyrAla 650
|||||
Db 1774 -----GAAGTCTTCATCTCTGATGTGCTCTGTCGCCA 1809
QY 651 MetArgGlnTyrPheLeuLysValLysAsnGlnMetIleLeuPheGlyGluGluAspVal 670
::: |||||
Db 1810 CAAGTGAAGATGTTGTT-----TTGTTTCTCTACAGGAGGAGGATGTG 1854
QY 671 ArgValAlaAsnLeuLysProArgIleSerPheAsnPhePheValThrAlaProLysAsn 690
|||||
Db 1855 CGAGTGGCTAAATTTGAACCAAGAAATCTCCTTTAATTTCTTTGTCACCTGACCTTAAAT 1914
QY 691 ValSerAspIleIleProArgThrGluValGluLysAlaIleArgMetSerArgSerArg 710
|||||
Db 1915 GTCTCTGATATCATCTCTAGAACTCAAGTTGAAAGGCCATCAGGATGTCCCGAGCCGT 1974
QY 711 IleAsnAspAlaPheArgLeuAsnAspAsnSerLeuGluPheLeuGlyIleGlnProThr 730
|||||
Db 1975 ATCAATGATGCTTTCGCTGTAATGACACAGCCCTGAGAGTTCTGGGGATACAGCCAAACA 2034
QY 731 LeuGlyProProAsnGlnProValSerIleTrpLeuIleValPheGlyValValMet 750
|||||
Db 2035 CTTGGACCTCTTAACAGCCCTCTTCCATATGCTGATGTTTGGAGTTGTGATG 2094
QY 751 GlyValIleValGlyIleValIleLeuIlePheThrGlyIleArgAspArgLysLys 770
|||||
Db 2095 GGAGTGATAGTGTGGCATGTCTATCTCTGATCTTCACTGGGATCAGAGATCGGAAGAG 2154
QY 771 LysAsnLysAlaArgSerGlyGluAsnProTyrAlaSerIleAspIleSerLysGlyGlu 790
|||||
Db 2155 AAAAATAAGCAAGAGTGGAGAAATCTTATGCTCCATCGATATTAGCAAGAGGAGAA 2214
QY 791 AsnAsnProGlyPheGlnAsnThrAspAspValGlnThrSerPhe 805
|||||
Db 2215 AATAATCCAGGATTCAAACACTGATGATGTTCAGACCTCCTTT 2259
RESULT 9
AAC84368
ID AAC84368 standard; cDNA; 2638 BP.
XX
AC AAC84368;
XX
DT 19-MAR-2001 (first entry)
XX
DE Mouse Zace2-5 protein encoding cDNA.
XX
KW Zace2; metalloenzyme; angiotensin-converting enzyme; ACE; fertility;
KW zinc metalloproteinase; blood pressure; zinc protease; hypertension;
KW ventricular systolic dysfunction; renal impairment; heart failure;
KW scleroderma renal crisis; atherosclerosis; . antiinflammatory; mouse;
KW antiarthritic; bradykinin inactivator; ss.
XX
OS Mus sp.
XX
FH Location/Qualifiers
FT 106..2523
FT /*tag= a
FT /product= "zace2-5"
FT /note= "the coding fragment is specifically claimed for"
XX
XX WO2000070032-A1.
XX
XX 23-NOV-2000.
XX
XX 03-MAY-2000; 2000WO-US11932.
XX
PF
```

```
XX 13-MAY-1999; 99US-0311482.
PR 27-AUG-1999; 99US-0384706.
XX
PA (ZYMO ) ZYMOGENETICS INC.
XX
PI Piddington CS, Petrie CR, Shoemaker KE, Bishop PD;
XX
XX WPI: 2001-025018/03.
DR P-PSDB; AAB48097.
XX
XX Angiotensin-converting enzyme, Zace2, useful for treating inflammatory
PT bowel disease, e.g. Crohn's disease and ulcerative colitis, or diseases
PT associated with inflammation such as arthritis and enterocolitis -
XX
XX Claim 10; Page 104-109; 125pp; English.
XX
XX The invention relates to the metalloenzyme Zace2. Zace2, an angiotensin-
CC converting enzyme is a zinc metalloproteinase that plays roles in blood
CC pressure regulation and fertility. Zace2 can be expressed by standard
CC recombinant methodology. Zace2 polypeptides are useful for treating an
CC inflammatory bowel disease (e.g. Crohn's disease and ulcerative colitis),
CC diseases associated with inflammation like arthritis and enterocolitis,
CC as targets for identifying modulators of zinc protease activity, for
CC screening or identifying new angiotensin-converting enzyme (ACE)
CC inhibitors, and as a basis for rational drug design for inhibitory
CC molecules. The nucleic acids can be used to detect the expression of a
CC Zace2 gene in a biological sample, as probes for in vivo diagnosis and
CC for detecting and localizing Zace2 gene expression in tissue samples,
CC to determine whether a subject's chromosomes contain a mutation in the
CC Zace2 gene, and to detect aberrations associated with the Zace2 locus.
CC Inhibitors of ACE are used for treating hypertension of various
CC conditions, including left ventricular systolic dysfunction, progressive
CC renal impairment, scleroderma renal crisis, congestive heart failure due
CC to dysfunction, and treatment of atherosclerosis. Zace2 agonists may be
CC used to treat infertility while Zace2 antagonists are used for inducing
CC infertility. The present sequence represents a cDNA encoding the mouse
CC Zace2-5 protein.
XX
SQ Sequence 2638 BP; 802 A; 556 C; 611 G; 669 T; 0 other;
```

```
Alignment Scores:
Pred. No.: 0 Length: 2638
Score: 3579.00 Matches: 661
Percent Similarity: 89.57% Conservative: 60
Best Local Similarity: 82.11% Mismatches: 84
Query Match: 83.41% Indels: 0
DB: 22 Gaps: 0
```

US-09-635-501-2 (1-805) x AAC84368 (1-2638)

```
QY 1 MetSerSerSerTrpLeuLeuLeuSerLeuValAlaValThrAlaAlaGlnSerThr 20
|||||
Db 106 ATGTCCAGCTCCCTCTGCTCTCTTCAGCCTTGTTGCTGTACTACTGCTCAGTCCCTC 165
QY 21 IleGluGluGlnAlaLysThrPheLeuAspLysPheAsnHisGluAlaGluAspLeuPhe 40
|||||
Db 166 ACCGAGGAAATCCAGACATTTTAAACAACTTTAATATCAGGAAGCTGAAGACTGTCT 225
QY 41 TyrGlnSerSerLeuAlaSerTrpAsnTyrAsnThrAsnIleThrGluGluAsnValGln 60
|||||
Db 226 TATCAAGTTTCACCTGCTCTTGGAAATTAATATACTTAACATTACTGAAGAAATGCCAA 285
QY 61 AsnMetAsnAsnAlaGlyAspLysTrpSerAlaPheLeuLysGluGlnSerThrLeuAla 80
|||||
Db 286 AAGATGATGATGAGGCTGCGCAAAATGGTCTGCTTTTATGAAGAAGACAGTCTAAGACTGCC 345
QY 81 GlnMetTyrProLeuGlnGluIleGlnAsnLeuThrValLysLeuGlnAlaLeu 100
|||||
Db 346 CAAAGTTTCTCACTACAGAAATCCAGACTCCGATCATCATCAAGCTCACTACAGGCCCTT 405
QY 101 GlnGlnAsnGlySerSerValLeuSerGluAspLysSerLysArgLeuAsnThrIleLeu 120
|||||
```


Db 406 CAGCAAAAGTGGGTCTTCAGCAGACTCTCAGCAGACAAGACAACAGTTGAACACAATTCGTG 465
Qy 121 AsnThrMetSerThrIleTyrSerThrGlyLysValCysAsnProAspAsnProGlnGlu 140
Db 466 AACACCATGAGCACCATTACAGTACTGCAAAAGTTTGCACCCCAAGAACCCACAAGAA 525
Qy 141 CysLeuLeuLeuGluProGlyLeuAsnGluIleMetAlaAsnSerLeuAspTyrAsnGlu 160
Db 526 TGCTTTATTTACTTGAGCCAGGATGGATGAATTAATGGGACAGACAGACATCAACATCT 585
Qy 161 ArgLeuTrpAlaTrpGluSerTrpArgSerGluValGlyLysGlnLeuArgProLeuTyr 180
Db 586 AGGCTCTGGCAGTGGAGGGCTGGAGGGCTGAGGTTGGCAAGCAGCTGAGGCCCTGTAT 645
Qy 181 GluGluTyrValValLeuLeuLysAsnGluMetAlaArgAlaAsnHisTyrGluAspTyrGly 200
Db 646 GAACAGATGTGGTACTGAAACAGAGATGGCAAGAGCAACAATATTAACGACTATGGG 705
Qy 201 AspTyrTrpArgGlyAspTyrGluValAsnGlyValAspGlyTyrAspTyrSerArgGly 220
Db 706 GATTATTGGAGGGGACTATGAAGCAGAGGAGGAGGAGGCTGCTACAACTATAACCGTAAC 765
Qy 221 GlnLeuIleGluAspValGluHisThrPheGluGluIleLysProLeuTyrGluHisLeu 240
Db 766 CAGTTGATGAAGATGTAGAACCTACTCTCGCAGAGATCAAGCCATTTGATGACATCTT 825
Qy 241 HisAlaTyrValArgAlaLysLeuMetAsnAlaTyrProSerTyrIleSerProIleGly 260
Db 826 CATGCCCTATGTGAGGAGGATGTGATGGATACCTACCCCTCCATACATCAGCCGACATGGA 885
Qy 261 CysLeuProAlaHisLeuLeuGlyAspMetTrpGlyArgPheTrpThrAsnLeuTyrSer 280
Db 886 TGCCTCCCTGCCATTTGCTTGTGTATATGTGGGTAGATTGTGGACAAATCTGTACCCCT 945
Qy 281 LeuThrValProPheGlyGlnLysProAsnIleAspValThrAspAlaMetValAspGln 300
Db 946 TTGACTGTTCCTTTCACACAAACCAACATAGATGTACTGATGCAATGATGAATCAG 1005
Qy 301 AlaTrpAspAlaGlnArgIlePheLysGluAlaGluLysPhePheValSerValGlyLeu 320
Db 1006 GGCTGGGATGCAGAAAGATATTCAAGAGGAGGAGAAATCTTTGTTCTCTGTGGCCTT 1065
Qy 321 ProAsnMetThrGlnGlyPheTrpGluAsnSerMetLeuThrAspProGlyAsnValGln 340
Db 1066 CCTCATATGACTCAAGGATCTGGGCAAACTCTATGTGCTGACTGACCCAGAGATGGCGG 1125
Qy 341 LysAlaValCysHisProThrAlaTrpAspLeuGlyLysGlyAspPheArgIleLeuMet 360
Db 1126 AAAGTTTCTGCCACCCACAGCTTGGGATCTGGGATCTGGGACACGGAGACTTCAGAAATCAAGATG 1185
Qy 361 CysThrLysValThrMetAspPheLeuThrAlaHisHisGluMetGlyHisIleGln 380
Db 1186 TGTACAAAGGTCAATGGCAACTTCTTGACAGCCCATCAGCATGGGACATCCAA 1245
Qy 391 TyrAspMetAlaTyrAlaAlaGlnProPheLeuLeuArgAsnGlyAlaAsnGluGlyPhe 400
Db 1246 TATGACATGGCATATGCCAGGCAACCTTCTCCTGCTAAGAAAGGAGCCCAATGAAGGGTTC 1305
Qy 401 HisGluAlaValGlyGluIleMetSerLeuSerAlaAlaThrProLysHisLeuLysSer 420
Db 1306 CATGAACCTGTTGGAGAAATCATCTCCTCTCTGAGCTACCCCAAGCATCTCAAAATCC 1365
Qy 421 IleGlyLeuLeuSerProAspPheGlnGluAspAsnGluThrGluIleAsnPheLeuLeu 440
Db 1366 ATTTGGCTCTTGGCCTCCGATTTTCAAGAGATAGCGAAACAGAGATAAACTCTCTACTG 1425
Qy 441 LysGlnAlaLeuThrIleValGlyThrLeuProPheThrTyrMetLeuLysTrpArg 460
Db 1426 AAACAGCATTTGACATTTGTGGAAACATACCTGTTTACTTACATGTTAGAAAGTGGAGG 1485
Qy 461 TrpMetValPheLysGlyGluIleProLysAspGlnTrpMetLysLysTrpTrpGluMet 480
Db 1486 TGGATGCTCTTGGGGTGAAATTCACAAAGAGCAGTGGATGAAAGAGTGGTGGGAGATG 1545

Qy 481 LysArgGluIleValValGlyValGluProValProHisAspGluThrTyrCysAspPro 500
Db 1546 AAGGGGAGATCGTGTGTGGTGGAGCCCTCTGCCATCATGATGAACATACTGTGACCCCT 1605
Qy 501 AlaSerLeuPheHisValSerAsnAspTyrSerPheIleArgTyrThrArgThrLeu 520
Db 1606 GCATCTCTGTTCATGTTTCTAATGATTAATCTCATTCTCGATATATACACAGGACCAAT 1665
Qy 521 TyrGlnPheGlnPheGlnGluAlaLeuCysGlnAlaAlaLysHisGluGlyProLeuHis 540
Db 1666 TACCAATTCAGATTTCAGAAAGCTCTTGTCAAGCAGCTTAAGTATAATATGTTCTCTGCAC 1725
Qy 541 LysCysAspIleSerAsnSerThrGluAlaGlyGlnLysLeuPheAsnMetLeuArgLeu 560
Db 1726 AAATGTGACATCTCAAAATCCACTGAAGCTGGGCAAGAGTTGCTCAAGATGTGAGTCT 1785
Qy 561 GlyLysSerGluProTrpThrLeuAlaLeuGluAsnValValGlyAlaLysAsnMetAsn 580
Db 1786 GGAATTCAGAGCCCTGGACAAAGCCTTGGAAATGTGTAGGAGCAAGGAATATGAT 1845
Qy 581 ValArgProLeuLeuAsnTyrPheGluProLeuPheThrTrpLeuLysAspGlnAsnLys 600
Db 1846 GTAAACACCATGCTCAATTAATCTTCCAAACCGCTTGTGTGACTGGCTGAAAGACAGCAAGAGA 1905
Qy 601 AsnSerPheValGlyTrpSerThrAspTrpSerProTyrAlaAspGlnSerIleLysVal 620
Db 1906 AATCTTTTGTGGGTGGAACACTGAATGAGGCCATATGCCGACCAAGCATTAAGTG 1965
Qy 621 ArgIleSerLeuLysSerAlaLeuGlyAspLysAlaTyrGluTrpAsnAspAsnGluMet 640
Db 1966 AGGATAAGCTTAAATCAGCTCTGGAGCTTAATGATATGAATGGACCAACCAAGCAATG 2025
Qy 641 TyrLeuPheArgSerSerValAlaTyrAlaMetArgGlnTyrPheLeuLysValLysAsn 660
Db 2026 TTCTGTGTCCGATCATCTGTGATATGCCATGAGAAAGTATTTTCAATAATCAAAAAAC 2085
Qy 661 GlnMetIleLeuPheGlyGluGluAspValArgValAlaAsnLeuLysProArgIleSer 680
Db 2086 CAGACAGTTCCTTTCTAGAGGAAGATGTACGAGTGGCGATTTGAAACCAAGATCTCC 2145
Qy 681 PheAsnPheValThrAlaProLysAsnValSerAspIleIleProArgThrGluVal 700
Db 2146 TTCTACTTCTTTGTCACCTCACCCCAAAATGTCTCTGATGATCATCTTAGAAGTCAAGTT 2205
Qy 701 GluLysAlaIleArgMetSerArgSerArgIleAsnAspAlaPheArgLeuAsnAspAsn 720
Db 2206 GAAGATGCCATCAGGATGTCTCGGGGCCCATCAATGATGTCTTTGGCTGAATGAATAC 2265
Qy 721 SerLeuGluPheLeuGlyIleGlnProThrLeuGlyProProAsnGlnProProValSer 740
Db 2266 AGCCTGGAGTTCTGGGATTCACCCCAACACTTGAGCCACCTTACCAGCCTCTCTGCACC 2325
Qy 741 IleTrpLeuIleValPheGlyValValMetGlyValIleValIleValGlyIleValIleLeu 760
Db 2326 ATATGGCTGATATTTTGTGTGTGTGGTGGCTGATGTGTGTGGCTGATCATCATCTG 2385
Qy 761 IlePheThrGlyIleArgAspArgLysLysAsnLysAlaArgSerGlyGlyGluAsnPro 780
Db 2386 ATTGCTACTGGGATCAAGGTCGAAAGAGAAAAATGAACAAAAAGAGAGAGAACCT 2445
Qy 781 TyrAlaSerIleAspIleSerLysGlyLysAsnAsnProGlyPheGlnAsnThrAspAsp 800
Db 2446 TATGACTCGATGGACATTTGAAAAGGAGAAAGCAATGCAGGATTCCTCAAAACAGTATGAT 2505
Qy 801 ValGlnThrSerPhe 805
Db 2506 GCTCAGACTTCTTT 2520

RESULT 10
AAC84370
ID AAC84370 standard; cDNA; 2638 bp.
XX

QY 361 CysThrLysValThrMetAspPheLeuThrAlaHisHisGluMetGlyHisIleGln 380
|||||
Db 1186 TGTACAAAGGTCACAAATTCCTGTGACAGCCCATCAGAGATGGGACATCAA 1245
QY 381 TyrAspMetAlaTyrAlaAlaGlnProPheLeuLeuArgAsnGlyAlaAsnGluGlyPhe 400
|||||
Db 1246 TATGACATGGCATATGCCAGGCAACCTTCTGCTAAGAAACGGAGCAATGAAGGTTTC 1305
QY 401 HisGluAlaValGlyGluIleMetSerLeuSerAlaAlaThrProLysHisIleLysSer 420
|||||
Db 1306 CATGAAGCTGTGGAGAAATCATGTCTCTTCAGCAGTACCCCAAGCATCTGAAATCC 1365
QY 421 IleGlyLeuLeuSerProAspPheGlnGluAspAsnGluThrGluIleAsnPheLeuLeu 440
|||||
Db 1366 ATTGGTCTCTGCCATCCGATTTTCAAGAAGATGCGAAGAACAGAGATAAATCTCTACTG 1425
QY 441 LysGlnAlaLeuThrIleValGlyThrLeuProPheThrTyrMetLeuGluLysTrpArg 460
|||||
Db 1426 AAACAGGCATTCACAATGTTTGGACACTACCGTTTACTTACATGTTAGAGAAGTGGAGG 1485
QY 461 TrpMetValPheLysGlyGluIleProLysAspGlnTrpMetLysLysTrpTrpGluMet 480
|||||
Db 1486 TGGATGGTCTTTCGGGGTGAATTCCTCAAGAGCAGTGGATGAAAGAGTGGTGGAGATG 1545
QY 481 LysArgGluIleValGlyValValGluProValProHisAspGluThrTyrCysAspPro 500
|||||
Db 1546 AAGCGGAGATCGTGGTGGTGAGAGCTCTGCCCTCGTGAGAACATACGTGACCCCT 1605
QY 501 AlaSerLeuPheHisValSerAsnAspTyrSerPheIleArgTyrTyrThrArgThrLeu 520
|||||
Db 1606 GCATCTCTGTCATGTTTCTAATGATTAATCTACTCATTCATTCGATATTACAAAGAGACCATT 1665
QY 521 TyrGlnPheGlnPheGlnGluAlaLeuCysGlnAlaAlaLysHisGluGlyProLeuHis 540
|||||
Db 1666 TACCAATTCAGTTTCAAGAAGCTCTTGTCAAGCAGCTTAAGTATAATGTTCTCTGAC 1725
QY 541 LysCysAspIleSerAsnSerThrGluAlaGlyGlnLysLysPheAsnMetLeuArgLeu 560
|||||
Db 1726 AAATGTGACATCTCAATTCACATGAAGCTGGCGAAGTGTCTCAAGATGCTGAGTCTT 1785
QY 561 GlyLysSerGluProTrpThrLeuAlaLeuGluAsnValValGlyAlaLysAsnMetAsn 580
|||||
Db 1786 GGAATTCAGAGCCCTGGACCGAAGCCTTGGAAATGTGGTAGGACAAAGGAATATGGAT 1845
QY 581 ValArgProLeuLeuAsnTyrPheGluProLeuPheThrTrpLeuLysAspGlnAsnLys 600
|||||
Db 1846 GTAAACCATCTGCTCAATTACTTCCAAACCGTGTGTGACTGGCTGAAAGCAGACAGCA 1905
QY 601 AsnSerPheValGlyTrpSerThrAspTrpSerProTyrAlaAspGlnSerIleLysVal 620
|||||
Db 1906 AATTCCTTTCTGGGGTGAACACTGAATGAGGCCATATGCCGACCAAAAGCATTTAAAGTG 1965
QY 621 ArgIleSerLeuLysSerAlaLeuGlyAspLysAlaTyrGluTrpAsnAspAsnGluMet 640
|||||
Db 1966 AGGATAAGCCTAAATCAGCTCTGTGGAGTAATGTCATATGAATGAGACCAACACGAATG 2025
QY 641 TyrLeuPheArgSerSerValAlaTyrAlaMetArgGlnTyrPheLeuLysValLysAsn 660
|||||
Db 2026 TTCTGTTCGATCATCTGTGTCATATGCCATGAGAAAGTATTCTTCAATAATCAAAAAC 2085
QY 661 GlnMetIleLeuPheGlyGluGluAspValArgValAlaAsnLeuLysProArgIleSer 680
|||||
Db 2086 CAGACAGTCTCTTCTAGAGAGAGATGTACGAGTGAGTGAATTTGAACCAAGAGTCTCC 2145
QY 681 PheAsnPheValThrAlaProLysAsnValSerAspIleIleProArgThrGluVal 700
|||||
Db 2146 TTCTACTCTTTGTGACCTCACCCCAAAATGTGTGATGTCATCTCTAGAGATGAAGTT 2205
QY 701 GluLysAlaIleArgMetSerArgSerArgIleAsnAspAlaPheArgLeuAsnAspAsn 720
|||||
Db 2206 GAAGATCCCATCAGGATGTCGCGGGCCGCATCAATGATGTCCTTGGCCCTGAATGATAAC 2265

QY 721 SerLeuGluPheLeuGlyIleGlnProThrLeuGlyProProAsnGlnProProValSer 740
|||||
Db 2266 AGCGTGGAGTTCTGGGGATTACCCAAACACTTGAGCCCTTACCAGCCTCTCTGTACCC 2325
QY 741 IleTrpLeuIleValPheGlyValValMetGlyValIleValValGlyIleValIleLeu 760
|||||
Db 2326 ATATGGCTGATTAATTTTGGTGTGTGTGATGGCACTGGTAGTGGTGGCATCATCTCTG 2385
QY 761 IlePheThrGlyIleArgAspArgLysLysAsnLysAlaArgSerGlyGluAsnPro 780
|||||
Db 2386 ATTGTCACTGGATCAAAAGCTCGAAAGAGAAAATGAAAAAGAGAGAGAACCCCT 2445
QY 781 TyrAlaSerIleAspIleSerLysGlyGluAsnAsnProGlyPheGlnAsnThrAspAsp 800
|||||
Db 2446 TATGACTCGATGGACATTCGAAAAGGAGAAAGCAATGCAGGATTCCAAAAACAGTGATGAT 2505
QY 801 ValGlnThrSerPhe 805
|||||
Db 2506 GTCAGACTTCCCTTT 2520
RESULT 11
AAC84367
ID AAC84367 standard; DNA; 2415 BP.
XX AAC84367;
XX
DT 19-MAR-2001 (first entry)
XX
DE Human Zace2 protein encoding degenerate sequence.
XX
KW Zace2; metalloenzyme; angiotensin-converting enzyme; ACE; fertility;
KW zinc metalloproteinase; blood pressure; zinc protease; hypertension;
KW ventricular systolic dysfunction; renal impairment; heart failure;
KW scleroderma renal crisis; atherosclerosis; antiinflammatory; human;
KW antiarthritic; bradykinin inactivator; ds.
XX
OS Homo sapiens.
XX
PN WO200070032-Al.
XX
PD 23-NOV-2000.
XX
XX 03-MAY-2000; 2000WO-US11932.
XX
XX 13-MAY-1999; 99US-0311482.
PR 27-AUG-1999; 99US-0384706.
XX
PA (ZYMO) ZYMOGENETICS INC.
XX
XX Piddington CS, Petrie CR, Shoemaker KE, Bishop PD;
XX
XX WPI; 2001-025018/03.
DR P-PSDB; AAB48095.
DR
XX
XX Angiotensin-converting enzyme, Zace2, useful for treating inflammatory
XX bowel disease, e.g. Crohn's disease and ulcerative colitis, or diseases
XX associated with inflammation such as arthritis and enterocolitis -
XX
XX Disclosure; Page 103-104; 125pp; English.
XX
XX The invention relates to the metalloenzyme Zace2. Zace2, an angiotensin-
XX converting enzyme is a zinc metalloproteinase that plays roles in blood
XX pressure regulation and fertility. Zace2 can be expressed by standard
XX recombinant methodology. Zace2 polypeptides are useful for treating an
XX inflammatory bowel disease (e.g. Crohn's disease and ulcerative colitis),
XX diseases associated with inflammation like arthritis and enterocolitis,
XX as targets for identifying modulators of zinc protease activity, for
XX screening or identifying new angiotensin-converting enzyme (ACE)
XX inhibitors, and as a basis for rational drug design for inhibitory
XX molecules. The nucleic acids can be used to detect the expression of a
XX Zace2 gene in a biological sample, as probes for in vivo diagnosis and
XX for detecting and localizing Zace2 gene expression in tissue samples,
XX to determine whether a subject's chromosomes contain a mutation in the

CC Zace2 gene, and to detect aberrations associated with the Zace2 locus.
CC Inhibitors of ACE are used for treating hypertension of various
CC conditions, including left ventricular systolic dysfunction, progressive
CC renal impairment, scleroderma renal crisis, congestive heart failure due
CC to dysfunction, and treatment of atherosclerosis. Zace2 agonists may be
CC used to treat infertility while Zace2 antagonists are used for inducing
CC infertility. The present sequence represents a degenerate sequence
CC encoding the human Zace2 protein.
XX

SQ Sequence 2415 BP; 494 A; 218 C; 398 G; 335 T; 970 other;

Alignment Scores:

Pred. No.:	0	Length:	2415
Score:	3509.00	Matches:	644
Percent Similarity:	80.00%	Conservative:	0
Best Local Similarity:	80.00%	Mismatches:	161
Query Match:	81.78%	Indels:	0
DB:	22	Gaps:	0

US-09-635-501-2 (1-805) x AAC84367 (1-2415)

QY 1 MetSerSerSerSerTrpLeuLeuSerLeuValAlaValThrAlaAlaGlnSerThr 20
DB 1 ATGWSWSWSWSNSWGTGTYNTNTNWSNYTNGTNGCNGTACNGCNCNCARSNACN 60

QY 21 IleGluGluAlaLysThrPheLeuAspLysPheAsnHisGluAlaGluAspLeuPhe 40
DB 61 ATHGARGARGCARGCNAARACNTTYTNGAYAAARTTYAAYCAYGARGCNGARGAYTNTTY 120

QY 41 TyrGlnSerSerLeuAlaSerTrpAsnThrAsnThrAsnIleThrGluGluAsnValGln 60
DB 121 TAYCARWSNWSNYTNCNCNSNTGGAAATAYAAACNAAYATACNGARGARAAYGTNCAR 180

QY 61 AsnMetAsnAsnAlaGlyAspLysTrpSerAlaPheLeuLysGluGlnSerThrLeuAla 80
DB 181 AAYATGAAYACGCGNGGNGAYARTGGWSNGCNTTYTTHAARGCARSNACNTYNGCN 240

QY 81 GlnMetTrpProLeuGlnGluLeGlnAsnLeuThrValLysLeuGlnLeuAlaLeu 100
DB 241 CARATGAYCCNTNCARGARATHCARAAYTTCNACNGTNAARTNCARYTNCARGCNYTN 300

QY 101 GlnGluAsnGlySerSerValLeuSerGluAspLysSerLysArgLeuAsnThrIleLeu 120
DB 301 CARCARAAYGGNWSNNGTNTNWSNGARGAYAAARWSNAARMGNTTNAAYACNATHYTN 360

QY 121 AsnThrMetSerThrIleTyrSerThrGlyLysValCysAsnProAspAsnProGlnGlu 140
DB 361 AATACNATGWSNACNATHAYWSNACNGNNAARGTNTGYAACCGAYAAAYCCNCARGAR 420

QY 141 CysLeuLeuLeuGluProGlyLeuAsnGluIleMetAlaAsnSerLeuAspTyrAsnGlu 160
DB 421 TGYTYNTNTNGARCCNGNTNAYAGARATHATGCGNAAYWSNYTNGAYTAYAAAYGAR 480

QY 161 ArgLeuTrpAlaTrpGluSerTrpArgSerGluValGlyLysGlnLeuArgProLeuTyr 180
DB 481 MGNYYTGGCNGTGGGARWSNTGGMWSNGARGTNGGNAARCARNTNMGNCNTNTAY 540

QY 181 GluGluTyrValValLeuLysAsnGluMetAlaArgAlaAsnHisTyrGluAspTyrGly 200
DB 541 GARGARTYGTNTNTNAAAYAGARATGGCNGMGNGCAAYCAYTAYGARGAYTAYGNG 600

QY 201 AspTyrTrpArgGlyAspTyrGluValAsnGlyValAspGlyTyrAspTyrSerArgGly 220
DB 601 GAYTAYTGGMNGGNGAYTAYGARGTNAAYGGNGTNGAYGGTAYGAYTAYWSNMGNGN 560

QY 221 GlnLeuIleGluAspValGluHisThrPheGluGluIleLysProLeuTyrGluHisLeu 240
DB 661 CARYTNATHGARGAYGTNGARCAYACNTTYGARGARATHAARCCNTNTNAYGARCAYTN 720

QY 241 HisAlaTyrValArgAlaLysLeuMetAsnAlaTyrProSerTyrIleSerProIleGly 260
DB 721 CAYGCNTAYGTNMGNGCNAARTNATGAAYGCNTAYCCNWSNTAYATACNWSNCCNATHGNG 780

QY 261 CysLeuProAlaHisLeuLeuGlyAspMetTrpGlyArgPheTrpThrAsnLeuTyrSer 280
DB 781 TGYTTCNCNGCNCAYTNTYTNNGNGAYATGTGGGNGMNTTYTGACNAAYTNTAYWSN 840

QY 281 LeuThrValProPheGlyGlnLysProAsnIleAspValThrAspAlaMetValAspGln 300
DB 841 YTNACNGTNCNTTYGGNCARAARCCNAAAYATHGAYGTNACNGAYCCNGNAAAYGTNCAR 900

QY 301 AlaTrpAspAlaGlnArgIlePheLysGluAlaGluLysPhePheValSerValGlyLeu 320
DB 901 GCNTGGGAYGCNCARMGNATHTYAARGCARGCNGARAARTTYTGTNWSNGTNGGNTN 960

QY 321 ProAsnMetThrGlnGlyPheTrpGluAsnSerMetLeuThrAspProGlyAsnValGln 340
DB 961 CCNAAAYATGACNARGGNTTYTGGARAAYWSNATGYTNACNGCNCAYCAYGARATGGNCAYATHCAR 1020

QY 341 LysAlaValCysHisProThrAlaTrpAspLeuGlyLysGlyAspPheArgIleLeuMet 360
DB 1021 AARGCNGTNTGYCAYCCNACNGCNTGGGAYTNGGNAARGNGGAYTTYTMGNATHYTNATG 1080

QY 361 CysThrLysValThrMetAspPheLeuThrAlaHisHisGluMetGlyHisIleGln 380
DB 1081 TGYACNAAARGTNACNATGGAYGAYTYYTNACNGCNCAYCAYGARATGGNCAYATHCAR 1140

QY 381 TyrAspMetAlaTyrAlaAlaGlnProPheLeuLeuArgAsnGlyAlaAsnGluGlyPhe 400
DB 1141 TAYGAYATGGCNTAYGCGNCARCNCNTTYTNTNMGNAAYGGNGCNAAYGARGGNTTY 1200

QY 401 HisGluAlaValGlyGluIleMetSerLeuSerAlaAlaThrProLysHisLeuLysSer 420
DB 1201 CAYGARGCNGTNGGNGARATHATGWSNTNWSNGCNGCNCNCAARCAAYTNAARWSN 1260

QY 421 IleGlyLeuLeuSerProAspPheGlnGluAspAsnGluThrGluIleAsnPheLeuLeu 440
DB 1261 ATHGGNYTNTNWSNCCNGAYTTCARGARGAAYAGARGACNGARATHAAYTNTYNTN 1320

QY 441 LysGlnAlaLeuThrIleValGlyThrLeuProPheThrTyrMetLeuGluLysTrpArg 460
DB 1321 AARCARGCNTNACNATHGTNGGNACNTNCCNTTYACNTATAYCTYTGARAARTGGMGN 1380

QY 461 TrpMetValPheLysGlyGluIleProLysAspGlnTrpMetLysLysTrpTrpGluMet 480
DB 1381 TGGATGGTNTTYAARGGNGARATHCCNAAARGAYCARTCGATGAARAARTTGGGGARATG 1440

QY 481 LysArgGluIleValGlyValGluProValProHisAspGluThrTyrCysAspPro 500
DB 1441 AARMGNGARATHGTNGGNGTNGTNGARCCNGTNCNCNCAYGAYGARACMTATGTGAYCCN 1500

QY 501 AlaSerLeuPheHisValSerAsnAspTyrSerPheIleArgTyrThrArgThrLeu 520
DB 1501 GCNWSNYTNTTYCAYGTNWSNAAAYCAYTAYWSNTTYATHMGNNTAYTAYACNMGNACNTN 1560

QY 521 TyrGlnPheGlnPheGlnGluAlaLeuCysGlnAlaAlaLysHisGluGlyProLeuHis 540
DB 1561 TAYCARTTYCARTTYCARGARGCNTNTGYCARGCNGCNAARCAAYGARGGNCNTNCAAY 1620

QY 541 LysCysAspIleSerAsnSerThrGluAlaGlnLysLeuPheAsnMetLeuArgLeu 560
DB 1621 AARTGYGATATHWSNAAAYWSNACNGCNGCNGCNAARAYNTTYAATATGTTNMGNTN 1680

QY 561 GlyLysSerGluProTrpThrLeuAlaLeuGluAsnValValGlyAlaLysAsnMetAsn 580
DB 1681 CGNAAARWSNGARCCNTGGACNTNCGNTNGARAAYGTNGTNGGNGCNAARAAYATGAAY 1740

QY 581 ValArgProLeuLeuAsnTyrPheGluProLeuPheThrTrpLeuLysAspGlnAsnLys 600
DB 1741 GTNMGNCNTNTYNTAAAYTAVTYYGARCNTNTTYACNTTGGYTNAAARGAYCARAAYAR 1800

QY 601 AsnSerPheValGlyTrpSerThrAspTrpSerProTyrAlaAspGlnSerIleLysVal 620
DB 1801 AAYWSNTTYGTNGGNTGWSNACNGAYTGGWSNCCNTAYGCGNAYGARCWSNATHAARTN 1860

QY 621 ArgIleSerLeuLysSerAlaLeuGlyAspLysAlaTyrGluTrpAsnAspAsnGluMet 640

Db 453 AGCCACAAATCTTAACAGTAACGTGGAACACGTGTAACCCAGATAATCCACAAAGATGCT 512
QY 142 euLeuLeuGluProGlyLeuAsnGluIleMetAlaAsnSerLeuAspTyrAsnGluArgL 162
Db 513 TATTACTGAACACAGTTTGAATGAATTAATGGCAACAGTTTAGACTACAATGAGAGCG 572
QY 162 euTrpAlaTrpGluSerTrpArgSerGluValGlyLysGlnLeuArgProLeuTyrGluG 182
Db 573 TCTGGGCTTGGGAAGCTGGAGATCTGAGGTGGCAAGCAGCTGAGGCCATTATATGAAG 632
QY 182 luTyrValValLeuLysAsnGluMetAlaArgAlaAsnHisTyrGluAsp-Tyr-GlyAs 201
Db 633 AGTATGTGGTCTTGAATAATGAGATGGCAAGACCAATCAATTATGAGGACTTATTGGGA 692
QY 201 pTyrTrpArgGlyAspTyrGluValAsnGlyValAsp---GlyTyrAspTyrSerArgL 220
Db 693 TTATTGGAGAGAGACTATGAAGTAATGGGTAAATAGTGGATATGATACAGCGCGG 752
QY 220 yGlnLeuIleGluAspValGluHisThr-PheGluGluIleLysProLeuTyr-GluHis 239
Db 753 CCAGTTGATTAAGATGTGGAACATACCTGTGTAAGAGATTAAACATTGATAGGAACAT 812
QY 240 LeuHisAlaTyrValArgAlaLysLeuMetAsnAlaTyrProSerTyrIleSerProIle 259
Db 813 CTTACCCCTATGTGAGGGCCAAAGTTGATGAATGGCTATCTCTATATCATGATCCAAAT 872
QY 260 GlyCysLeuProAlaHisLeuLeuGlyAspMetTrp-GlyArgPheTrpThrAsnLeuTy 279
Db 873 GGATGCTCCCTGCTCATTTGCTGGTGATGTGCGGGTAGATTTGGACAAATCTGTGA 932
QY 279 rSerLeuThrValProPheGlyGlnLysProAsnIleAspValThrAspAlaMetValAs 299
Db 933 CTCCTTTGACAGTTCCTTTGGACAGAAACCAACATAGATGTTACTGATGCAATGGTGA 992
QY 299 pGlnAlaTrpAspAlaGlnArgIlePheLysGluAla-GluLysPhePheValSerValG 319
Db 993 CCAGGCTGGGATGGACAGAGAATATCAAGAGTCCGACAGCTCTTGTGTATCTGTG 1052
QY 319 lYleuProAsnMetThrGlnGlyPheTrp-GluAsnSerMetLeu-ThrAspProGlyAs 338
Db 1053 GTCCTCTTATATGACTCTAGGATTCGCGGCAAAATTCATGCTATAGCGCCACAGGAA 1112
QY 338 nValGlnLysAlaValCysHis-ProThrAlaTrpAspLeuGlyLysGlyAspPheArg- 357
Db 1113 TGTTCAGAAAGCACTCTGCCATCCACAGCTTGGGAGCTGGGGAAGGCGACTTCAGAG 1172
QY 358 lIleLeuMetCysThrLys-ValThrMetAspPheLeuThrAlaHisGluMetG1 377
Db 1173 ATCCTTATGTGCACAAAGGGTAACAAATGGACGACTTCCTGACAGCTCATATGAGATGG 1232
QY 377 yHisIleGlnTyrAspMetAlaTyrAlaAlaGlnPro-PheLeuLeuArg-AsnGlyAla 396
Db 1233 GCATATCCAGTATGATATGGCATATGCCGCAACCTTTTCTGCTAAGGAATGGAGCT 1292
QY 397 -AsnGluGlyPheHisGluAlaValGlyGluIleMetSerLeuSerAlaAlaThrProLy 416
Db 1293 TAATGAAGGATTTCCATGAAGCTGTTGGGAAATCATGTCTCACTTCTGCAGCCACACCTAA 1352
QY 416 shiLeuLysSerIleGlyLeuLeuSerProAspPheGln---GluAspAsnGluThrG1 435
Db 1353 GCATTTAAATCCATTGCTCTCTGTCACCCGAGTTTCAACGACGACGAATGAACAGA 1412
QY 435 uIleAsnPheLeuLeuLysGlnAlaLeuThrIleValGlyThrLeuProPheThrTyrMe 455
Db 1413 AATAAACATTCCTGCTCAAAACAGCACTCACGATTGTTGGGACTCTGGCACTTACTTACT 1472
QY 455 tIleuGluLysTrpArgTrpMetValPheLys-GlyGluIleProLysAspGlnTrpMetL 475
Db 1473 GTTAGAAGTGGAGGTGGATGGTCTTTAAACGGGGAAATTTCCCAAGACCACTGGGGA 1532
QY 475 ySLys-TipTrpGluMetLysArgGlu-IleValGlyVal-ValGluProValProHisA 494
Db 1533 AAAGGTGGTGGAGATGAAGCGAAAGAATAGTTGGGGGTGTGTGGAACTGTGCCCATG 1592

QY 494 spGluThrTyr-CysAspProAlaSerLeuPheHisValSerAsnAspTyrSerPheIle 513
Db 1593 ATGAACAATATCTGTGACCCGCACTCTGTGTCCATGTTTCTAATGATTACTCATTCATT 1652
QY 514 ArgTyrTyrThrArgThrLeu-TyrGlnPheGlnPheGln-GluAlaLeu-CysGlnAla 532
Db 1653 CGATATTACACAAGGACCCCTGTTACCAATTCAGTTTCAAAGAGGACACTTTTGTCAAGCA 1712
QY 533 AlaLysHisGluGlyProLeuHisLys-CysAspIle-SerAsnSerThrGlu---AlaG 551
Db 1713 GCTAAACATGAAGGCCCTCTGCACAAATGTGACATTCTCAATTTCTACAGAAGCTCGT 1772
QY 551 lYglnLys-LeuPheAsnMetLeuArgLeuGlyLys-SerGluProTrpThrLeuAlaLe 570
Db 1773 GACAAACACTGTTCATATATGCTGAGGCTTGGAAACCTCAGAACCCCTGGACCTTAGCAT 1832
QY 570 uGluAsnValVal-GlyAlaLysAsnMetAsnValArgPro-LeuLeuAsnTyrPheGlu 589
Db 1833 GGAAATGTTGTAAGGACCAAGAACAATGAATGTAAAGCCCACTGCTCAACTACTTTGAG 1892
QY 590 ProLeuPheThrTrpLeuLysAspGlnAsnLysAsnSerPheValGlyTrpSerThrAsp 609
Db 1893 CCCTTATTACCTGGCTGAAAGACCAAGCAAGAAATCTTTTGTGGATGGAGTACCGAC 1952
QY 610 TrpSerProTyrAlaAspGlnSerIle-LysValArgIleSerLeuLysSerAlaLeuG1 629
Db 1953 TGGAGTCCATATGACAGACCAGCATCACAAAGTAGGATAAGCCCTAAAATCAGCTCTTGG 2012
QY 629 y-AspLysAlaTyrGluTrpAsnAsp-AsnGluMetTyrLeuPheArgSerSer-ValAl 648
Db 2013 CAGATAAGCATATGAATGGACCCCAATGAATGTACCTGTTCCGATCATCTGGTTGG 2072
QY 648 aTyrAla---MetArgGlnTyrPheLeu-LysValLysAsnGlnMetIleLeuPheGlyG 667
Db 2073 ATATTGTTAATGAGGAGTAGTACTTTTAAACAAGTAAAAATCAGATGATCTTTTGGGG 2132
QY 667 luGluAspValArgValAlaAsnLeuLysProArgIleSerPheAsnPhePheValThrA 687
Db 2133 AGGAGGATGTCCGAGTGGCTAAATTTGAAACCAAGAATCTCCTTTTAATTTCTTGTCACTG 2192
QY 687 laProLysAsnValSer-AspIleIleProArg-ThrGluValGluLysAlaIleArgMe 706
Db 2193 CACCTAAAAATGCTCTGGATATCATTCCTAGAAACTGAAGTTGAAAAGGCCATCAGAT 2252
QY 706 tSerArgSerArg-IleAsnAspAlaPheArgLeuAsnAspAsnSerLeuGluPheLeuG 726
Db 2253 GTCCCGGAGCGGTACTCCATGATGCTTTCGCTCTGAATGACGACGCTAGAGTTTCTGG 2312
QY 726 lYlleGlnProThrLeuGlyProAsnGlnProProValSerIleTrpLeuIleValP 746
Db 2313 GGATACACCCAACTTGGACCTCTAACGACCCCTGTTTCCATATGGCTGATGTTT 2372
QY 746 heGlyValValMetGlyValIleValValGly-IleValIleLeu-IlePheThrGlyI 765
Db 2373 TTGAGTTGTGATGGGAGTGATAATTGTTGGCCATGCTCATCTCTGGATCTTCACTGGAAT 2432
QY 765 eArgAspArgLysLysLysAsnLysAlaArgSerGlyGlu-AsnPro-TyrAlaSerIle 784
Db 2433 CAGAGATCGGAAGAAGAAAAATAAGCAAGAGTGGAGAATAATCTCTTTTATGCTCCATC 2492
QY 785 AspIleSerLysGlyGlu---AsnAsnProGlyPheGlnAsnThrAspAspValGlnThrS 804
Db 2493 GATATTAGCTAAGGAGTATAAATAATCCAGATTCCGAAACACTGATGATGTTTCAGACCT 2552
QY 804 erPhe 805
Db 2553 CCTTT 2557
RESULT 13
AAC84369
ID AAC84369 standard; DNA; 2415 BP.
XX

Qy	381	TyrAspMetAlaTyrAlaAlaGlnProPheLeuLeuArgAsnGlyAlaAsnGluGlyPhe	400
Db	1141	TAYGAYTGCGNTAYCGMGCNCAACCNTTYTNTYTMGNAAYGGGCAAYGARGGNTTY	1200
Qy	401	HisGluAlaValGlyGluIleMetSerLeuSerAlaAlaThrProLysHisLeuLysSer	420
Db	1201	CAYGARGCNTGGNGARGATHATGWSNYTNWSGNCNGCNACNCCNAARCAITYTNAARWSN	1260
Qy	421	IleGlyLeuLeuSerProAspPheGlnGluAspAsnGluThrGluIleAsnPheLeuLeu	440
Db	1261	ATHGGNTNTNCCNSNGAYTTYCARGARGAYWSNGARCANARGARATHAAATYTTYTNTYN	1320
Qy	441	LysGlnAlaLeuThrIleValGlyThrLeuProPheThrTyrMetLeuGluLysTrpArg	460
Db	1321	AARCAARGCNTNACNATHGTGNGNACNTNCCNTTYACNTATATGTYTNGAARATGCMGN	1380
Qy	461	TrpMetValPheLysGlyGluIleProLysAspGlnTrpMetLysLysTrpTrpGluMet	480
Db	1381	TGGATGCTNTTYMGNGNGARGATHCCNAARGCARTCGATCAARAATGTGTGGARATG	1440
Qy	481	LysArgGluIleValGlyValValGluProValProHisAspGluThrTyrCysAspPro	500
Db	1441	AARMGNGARATHGTGNGCTNGTGARCCNTNCCNCAYGAYGARACNTATGTGATCCN	1500
Qy	501	AlaSerLeuPheHisValSerAsnAspTyrSerPheIleArgTyrThrArgThrLeu	520
Db	1501	GCNWSNTNTTYCAYGTNWSNAAYGAYTAYWSNTTYATHMGNATYATACNMGNACNATH	1560
Qy	521	TyrGlnPheGlnPheGlnGluAlaLeuCysGlnAlaAlaLysHisGluGlyProLeuHis	540
Db	1561	TATCARTTYCARTTYCARGARCCNTNTGYCARGCGNCAARTAYAYGGNWSNYTNCAY	1620
Qy	541	LysCysAspIleSerAsnSerThrGluAlaGlyGlnLysLeuPheAsnMetLeuArgLeu	560
Db	1621	AARTGYGAYATHWSNAAYWSNACNARGCNGCNCARAARYTNTYNAARATGYTNWSNTYN	1680
Qy	561	GlyLysSerGluProTrpThrLeuAlaLeuGluAsnValValGlyAlaLysAsnMetAsn	580
Db	1681	GGNAAYWSNGARCCNTGGACNARGCNTNGARAAYGTNGTNGCNGCMNGNAAYATGGAY	1740
Qy	581	ValArgProLeuLeuAsnTyrPheGluProLeuPheThrTrpLeuLysAspGlnAsnLys	600
Db	1741	GTNAARCCNTNTYNAAYTATYTYCARCCNTNTTYGAYTGGYTYNAARGCARCAAYMGN	1800
Qy	601	AsnSerPheValGlyTrpSerThrAspTrpSerProTyrAlaAspGlnSerIleLysVal	620
Db	1801	AAWWSNTTYGTNGNTGGAAAYACNARGTGGWSNCCNTAYCGCAYCARWSNATHAARGTN	1860
Qy	621	ArgIleSerLeuLysSerAlaLeuGlyAspLysAlaTyrGluTrpAsnAspAsnGluMet	640
Db	1861	MGNATHWSNTYNAARWSNCGNTNGGNCNAAYGCNTAYGARTGGACNAAYAYGARATG	1920
Qy	641	TyrLeuPheArgSerSerValAlaTyrAlaMetArgGlnTyrPheLeuLysValLysAsn	660
Db	1921	TTYTYTNTTYMGWSWSNGTNGCNTAYGCNATGNAARTAYTTYWSNATHATHAARAAY	1980
Qy	661	GlnMetIlePhePheGlyGluGluAspValArgValAlaAsnLeuLysProArgIleSer	680
Db	1981	CARACNGTNCCTTYTNGARGARGAYGTNMNGTGNWSGAYTYNAARCCNMGNGTWSN	2040
Qy	681	PheAsnPheValThrAlaProLysAsnValSerAspIleIleProArgThrGluVal	700
Db	2041	TTYTATYTTTTYGTGNACNWSNCCNARAAYGTNWSGAYGTNATCCNMGWSNGARGTN	2100
Qy	701	GluLysAlaIleArgMetSerArgSerArgIleAsnAspAlaPheArgLeuAsnAspAsn	720
Db	2101	GARGAYGCNATHMGNATGWSNMNGNGNGNATHAAYGAYGTNTYGGNTYNAAYGAYAY	2160
Qy	721	SerLeuGluPheLeuGlyIleGlnProThrLeuGlyProProAsnGlnProProValSer	740
Db	2161	WSNYTNGARTTYTYTNGGNATHCAVCCNACNCTYNGARCCNCCNTAYCARCCNCCNATCN	2220
Qy	741	IleTrpLeuIleValPheGlyValValIleValGlyValIleValGlyValIleLeu	760

Db	2221	ATHTGGYNATHATHTTYGCGINGTNGTGCNWTGCTGTGNGGNATHATHATHTN	2280
Qy	761	IlePheThrGlyIleArgAspArgLysLysAsnLysAlaArgSerGlyGluAsnPro	780
Db	2281	ATHGTNACGGNATHTAARGGWMGNARAARAARAAYGARACNAARMGNGARGAAYCCN	2340
Qy	781	TyrAlaSerIleAspIleSerLysGlyGluAsnAsnProGlyPheGlnAsnThrAspAsp	800
Db	2341	TAYGAYNSATGGAYATHGGNAARGGARWSNAAYGCGNGTTCYCARAAYWSNGAYGAY	2400
Qy	801	ValGlnThrSerPhe 805	
Db	2401	GCNCARACNWSNTTY 2415	
RESULT 14			
ID	AAQ10328	standard; DNA; 2477 BP.	
XX	AC	AAQ10328;	
XX	AC		
DT	10-APR-1991	(first entry)	
XX		Encodes human testicular angiotensin conversion enzyme.	
DE		human testicular angiotensin conversion enzyme; tACE;	
KW		male sterility; ss.	
XX		Homo sapiens.	
OS			
FH	Key	Location/Qualifiers	
FT	CDS	29..2227	
FT		/*tag= a	
FT		/product= human tACE	
FT	Peptide	29..91	
FT		/*tag= b	
FT		/label= signal peptide	
XX			
PN	W09100354-A.		
XX			
PD	10-JAN-1991.		
XX			
PF	05-JUL-1990;	90WO-FR00513.	
XX			
PR	05-JUL-1989;	89FR-0009062.	
XX			
PA	(INRM) INST NAT SANTE RECH.		
XX			
PI	Soubrier F, Alhenc-Gelas F, Hubert C, Corvol P;		
XX			
DR	WPI: 1991-036748/05.		
DR	P-PSDB; AAR10426.		
XX			
PT	Nucleic acid - encoding human testicular angiotensin conversion enzyme, used e.g. for in vitro detection of enzyme in organism		
XX			
PS	Claim 1; Fig 1; 48pp; French.		
XX			
CC	A bank of human testicular cDNA in Lambda gt11 was screened with a probe containing the final 3248 nucleotides of endothelial ACE. The complete sequence of tACE was reconstructed from 4 separate clones. It encodes a 711 amino acid mature protein and a 21 residue signal peptide. The 228-2224 sequence is identical to the 1944-3940 region of endothelial ACE. The isolated nucleic acid sequence is inserted into a plasmid for expression of polypeptides. The invention also covers parts of the sequence comprising all or part of the 29-229 sequence, any sequence differing from tACE only by silent substitutions and nucleic acids which hybridise to tACE.		
XX			
SQ	Sequence 2477 BP; 536 A; 811 C; 595 G; 435 T; 0 other;		
Alignment Scores:			
Pred. No.:	6.37e-121	Length:	2477

Alignment Scores:	6.37e-121	Length:	2477
Pred. No.:			

Score: 1344.00 Matches: 259
Percent Similarity: 60.97% Conservative: 119
Best Local Similarity: 41.77% Mismatches: 204
Query Match: 31.32% Indels: 38
DB: 12 Gaps: 10

US-09-635-501-2 (1-805) x AAQ10328 (1-2477)

QY 15 ThrAlaAlaGlnSer-----ThrIleGluGluGlnAlaLysThrPheLeuAsp 30
DB 209 ACATCGCCAGAGCCCAAACTGGTACTGATGAGCTGAGGCCAGCAACTTTGTGGAG 268
QY 31 LysPheAsnHisGluAlaGluAspLeuPheTyrglnSerSerLeuAlaSerTrpAsnTyr 50
DB 269 GAATATGACCGGACATCCAGGTGGTGTGAACGAGTATGCCGAGGCAACTGGAACCTAC 328
QY 51 AsnThrAsnIleThrGluGlu-----AsnValGlnAsnMet 62
DB 329 AACACCAACATCACACAGACACCAAGATTCGTGCGAAGAACATGCAAAATAGCC 388
QY 63 AsnAsnAlaGlyAspLysTrpSerAlaPheLeuLysGluGlnSerThrLeuAlaGlnMet 82
DB 389 AACACACC-----CTGAAGTACGGCCAGCCAGGAGGAG 424
QY 83 TyrProLeuGlnGluIleGlnAsnLeuThrValLysLeuGlnLeuAlaLeuGlnGln 102
DB 425 TTTGATGTGAACCATGTCAGAACACCACTATCAAGCGGATCATAAAGAGGTTTCAGGAC 484
QY 103 AsnGlySerSerValLeuSerLysAspLysSerLysArgLeuAsnThrIleLeuAsnThr 122
DB 485 CTGAAACGGGCGCGCTGCTCCAGAGCTGGAGGAGTACAAACAGATCTGTGGAT 544
QY 123 MetSerThrIleTyrSerThrGlyLysValCysAsnProAspAsnProGlnGluCysLeu 142
DB 545 ATGGAACACCATACAGCTGCCACTGTGTGCCACCGCAATGGC-----AGCTGCCGTG 598
QY 143 LeuLeuGluProGlyLeuAsnGluIleMetAlaAsnSerLeuAspTyrAsnGluArgLeu 162
DB 599 CAGCTCGAGCCAGATGTGACGAATGTGATGGCCACATCCCGGAAATATGAAGACCTGTTA 658
QY 163 TrpAlaTrpGluSerTrpArgSerGluValGlyLysGlnLeuArgProLeuTyrGluGlu 182
DB 659 TGGCATGGAGGCTGGCGACACAGAGGGGGGAGAGCCATCTCCAGTTTACCCGAA 718
QY 183 TyrValValLeuLysAsnGluMetAlaArgAlaAsnHisTyrGluAspTyrGlyAspTyr 202
DB 719 TAGCTGGAACATCATCAACAGCTGCCCGCTCAATGGCTATGTAGATGCAGGGGACTCG 778
QY 203 TrpArgGlyAspTyrGluValAsnGlyValAspGlyTyrAspTyrSerArgGlyGlnLeu 222
DB 779 TGGAGGTCTATGTACGAGACACCATCCCTGGAG----- 811
QY 223 IleGluAspValGluHisThrPheGluIleLysProLeuTyrGluHisLeuHisAla 242
DB 812 ---CAGACTGGAGGGCTTTCAGAGAGCTGCACCACTTACCTCAACCTGCATGCC 868
QY 243 TyrValArgAlaLysLeuMetAsnAlaTyr---ProSerTyrIleSerProIleGlyCys 261
DB 869 TAGCTGCGCGGCGCTGCACCGCTCATCTACGGGGCCAGCACATCAACCTGGAGGGGCC 928
QY 262 LeuProAlaHisLeuLeuGlyAspMetTrpGlyArgPheTrpThrAsnLeuTyrSerLeu 281
DB 929 ATTCTGCTACCTGTGGGAAACATGTGGCGCGCACACCTGGTCCAACTATGACTGTG 988
QY 282 ThrValProPheGlyGlnLysProAsnIleAspValThrAspAlaMetValAspGlnAla 301
DB 989 GTGGTGCCTTCCCTTCAGCCCTCGATGGACACACAGAGGCTATGTAAAGCAGGGC 1048
QY 302 TrpAspAlaGlnArgIlePheLysGluAlaGluLysPhePheValSerValGlyLeuPro 321
DB 1049 TGGACGCCAGGAGGATGTTTAAGAGGCTGATGATTCTTCACCTCCCTGGGGCTGCTG 1108
QY 322 AsnMetThrGlnGlyPheTrpGluAsnSerMetLeuThrAspProGlyAsnValGlnLys 341

DB 1109 CCGTGCCTCCTGAGTCTTGGAAACAGTCTGATGCTGGAGAACCAACCGCGGGGAG 1168
QY 342 AlaValCysHisProThrAlaTrpAspLeuGlyLysGly---AspPheArgIleLeuMet 360
DB 1169 GTGGTGTGCCACCGCTCGGCTGGGACTTCTACAACGGCAAGGACTTCGGATCAAGCAG 1228
QY 361 CysThrLysValThrMetAspPheLeuThrAlaHisHisGluMetGlyHisIleGln 380
DB 1229 TGCACCAACCGTGAACCTGGAGGACCTGGTGGTGGCCACACAGAAATGGCCACATCCAG 1288
QY 381 TyrAspMetAlaTyrAlaLagLlnProPheLeuLeuArgAsnGlyAlaAsnGluGlyPhe 400
DB 1289 TATTTCATGACGTACAAAGACTTACCTGTGGCCCTTGAGGAGGGTGCCAAACCCGGCTTC 1348
QY 401 HisGluAlaValGlyGluIleMetSerLeuSerAlaAlaThrProLysHisLeuLysSer 420
DB 1349 CATGAGGCCATTTGGGACGTGTAGCCCTCAGTGTCTACGCCCAAGCACCTTGCACAGT 1408
QY 421 IleGlyLeuLeuSerProAspPheGlnGluAspAsnGluThrGluIleAsnPheLeu 440
DB 1409 CTCAACCTGTGACGATGAGGTGGCGAGC---GAGCATGACATCAACTTCTGTATG 1465
QY 441 LysGlnAlaLeuThrIleValGlyThrLeuProPheThrTyrMetLeuGluLysTrpArg 460
DB 1466 AAGATGCGCCCTTGACAGATCGCCTTTATCCCTTCAGCTACCTCGTCGATCAGTGGCG 1525
QY 461 TrpMetValPheLysGlyGluIleProLysAspGlnTrpMetLysLysTrpTrpGluMet 480
DB 1526 TGGAGGCTATTGTGTAAGCATCACCAGGAGAACTATAACCAAGGAGTGTGGAGGCTC 1585
QY 481 LysArgGluIleValGlyValValGluProValProHisAspGluThrTyrCysAspPro 500
DB 1586 AGGTGAAGTACCAAGGCGCTTGCCTCCAGTGGCCAGGACTCAAGTGTGACTTTGACCCA 1645
QY 501 AlaSerLeuPheHisValSerAsnAspTyrSerPheIleArgTyrTyrThrArgThrLeu 520
DB 1646 GGGCCCAAGTTCACATTCCTTCTAGCGTGCCTTACATCAGTACTTGTGTGAGTTCATC 1705
QY 521 TyrGlnPheGlnPheGlnGluAlaLysGlnAlaLysHisGluGlyProLeuHis 540
DB 1706 ATCCAGTTCAGTTCACGAGGCACTGTGCAGGCACTGGCCACACGCGGCCCTCGAC 1765
QY 541 LysCysAspIleSerAsnSerThrGluAlaGlyGlnLysLeuPheAsnMetLeuArgLeu 560
DB 1766 AAGTGTGACATCTACCAGTCCACGAGCGCGCGGCGCTGGCGCACCGCCATGAAGCTG 1825
QY 561 GlyLysSerGluProTrpThrLeuAlaLeuGluAsnValValGlyAlaLysAsnMetAsn 580
DB 1826 GGCCTCAGTAGCGCTGGCGGAAGCCATGCTGATCAGCGGCGCCAGCCCAACATGAGC 1885
QY 581 ValArgProLeuLeuAsnTyrPheGluProLeuPheThrTrpLeuLysAspGlnAsnLys 600
DB 1886 GCCTCGGCATGTTGAGCTACTTCAAGCGCTGTGCTGGCTGGCTCCGCGCAGGAAACAG 1945
QY 601 -----AsnSerPheValGlyTrp---SerThrAspTrpSerProTyrAlaAspGlnSer 617
DB 1946 CTGCATGGGAGAGCTGGCTGGCCCGCAGTACAACTGGAGCGCCGAACTCCGCTCGCTCA 2005

RESULT 15

AAA38330

ID AAA38330 standard; DNA; 4020 BP.

XX AAA38330;

AC AAA38330;

XX 21-AUG-2000 (first entry)

XX Human angiotensin-converting enzyme (ACE) coding region.

XX Angiotensin-converting enzyme gene; ACE; coding region; polymorphism;
KW polymorphic marker; cardiovascular disease; myocardial infarction;
KW unstable angina; hypertension; atherosclerosis; stroke; prognosis;
KW drug screening; treatment outcome; human; ds.

XX Homo sapiens.
 XX WO200022166-A2.
 XX PD 20-APR-2000.
 XX PF 13-OCT-1999; 99WO-IB01678.
 XX PR 14-OCT-1998; 98US-0104286.
 XX PR 14-OCT-1998; 98US-0104302.
 XX PA (EURO-) EURONA MEDICAL AB.
 XX PI Norberg LT, Andersson MK, Lindstrom PHR, Jonsson L;
 XX WPI; 2000-318010/27.
 XX Assessing cardiovascular status in humans involves comparing test
 PT polymorphic pattern comprising polymorphic positions within genes
 PT encoding specific proteins, with reference polymorphic pattern -
 XX Disclosure; Page 114-115; 126pp; English.
 XX The invention relates to a novel method of assessing the cardiovascular
 CC status in an individual and to newly identified polymorphisms in the
 CC genes encoding angiotensin-converting enzyme (ACE), angiotensin II
 CC receptor type 1 (AT1) and type 2 (AT2), angiotensinogen (AGT), renin,
 CC aldosterone synthase, endothelin receptor type A and beta-adrenergic
 CC receptors 1 and 2. The method comprises determining the sequence at one
 CC or more polymorphic positions within these genes, and comparing the
 CC pattern of polymorphisms from the individual with a reference polymorphic
 CC pattern obtained from a population of individuals exhibiting a
 CC predetermined cardiovascular disease status. The polymorphic markers are
 CC useful for determining the predisposition of an individual to
 CC cardiovascular disorders such as myocardial infarction, unstable angina,
 CC hypertension, atherosclerosis and stroke. They are also useful for
 CC predicting the likely cardiovascular status of a patient given a
 CC treatment regimen comprising administration of cardiovascular drugs
 CC (e.g., ACE inhibitors, beta-adrenergic receptor antagonists (beta-
 CC blockers) or calcium channel blockers). One or more polymorphic markers
 CC provides a basis for predicting the outcome of a treatment regimen.
 CC Fragments of the genes comprising a polymorphic site may be used as
 CC primers and probes for detecting genetic polymorphisms or in molecular
 CC library arrays for high throughput screening. The genes, and the proteins
 CC they encode are useful in the screening of potential cardiovascular
 CC drugs. Determination of an individual's polymorphic pattern reduces or
 CC eliminates trial and error in selecting a treatment for a particular
 CC individual cardiovascular patient. It also provides the ability to
 CC eliminate patients from clinical trials who are predicted to be
 CC non-responsive, or at a risk for an adverse response, to a particular
 CC treatment regimen. Adverse results in an early trial can be evaluated to
 CC identify polymorphic patterns so that the adverse results can be
 CC correlated with a sub-population of the test population, permitting
 CC exclusion of such sub-populations from the treatment group. Beneficial
 CC drugs can be approved for use in the appropriate population, thereby
 CC decreasing the number of patients required for a clinical trial, which in
 CC turn decreases the duration and cost of such trials. Sequences A38328 and
 CC A38330 represent, respectively, intron 16 and the coding region of
 CC the human ACE gene (GenBank X62855, J04144). The polymorphic sites
 CC identified are 375A/C, 582C/T, 731A/G, 1060G/A, 1215C/T, 2193G/A,
 CC 2328A/G, 2741G/T, 3132C/T, 3387T/C, 3503G/C, 3906G/A; and a deletion of
 CC nucleotides 1451-1783 in intron 16.
 XX S0 Sequence 4020 BP; 857 A; 1261 C; 1174 G; 728 T; 0 other;

Alignment Scores:
 Pred. No.: 6,14e-120 Length: 4020
 Score: 1337.00 Matches: 255
 Percent Similarity: 61.05% Conservative: 118
 Best Local Similarity: 41.73% Mismatches: 204
 Query Match: 31,16% Indels: 34
 DB: 21 Gaps: 9

US-09-635-501-2 (1-805) x AAA38330 (1-4020)
 QY 20 ThrileGluGluGlnAlaLysThrPheLeuAspLysPheAsnHisGluAlaGluAspLeu 39
 DB 1952 ACTGATGAGCTGAGGCCAGCAAGTTGTGGAGAAATATACCGGACATCCCGAGTGTG 2011
 QY 40 PheTyrGlnSerSerLeuAlaSerTyrAsnThrAsnThrAsnThrGluGlu----- 57
 DB 2012 TGGAAACGAGTATGCCGAGGCCAACTGCAACTACACACCAACATCACCACAGAGACCAGC 2071
 QY 58 -----AsnValGlnAsnMetAsnAlaGlyAspLysTyrSerAla 71
 DB 2072 AAGATTCTGTCAGAGAAACATGCAAAATAGCAACACACACC----- 2113
 QY 72 PheLeuLysGluGlnSerThrLeuAlaGlnMetTyrProLeuGlnGluLeuGlnAsnLeu 91
 DB 2114 -----CTGAAGTACGCCACCCAGGCCAGGAAGTTTGTATGTGAACCACTTGCAGAACACC 2167
 QY 92 ThrValLysLeuGlnLeuGlnAlaLeuGlnGlnAsnGlySerSerValLeuSerGluAsp 111
 DB 2168 ACTATCAAGCGGATCATAAAGAAAGTTTCAGGACCTAGAACGGCGCGCTGCTGCCAG 2227
 QY 112 LysSerLysArgLeuAsnThrLeuLeuAsnThrMetSerThrIleTyrSerThrGlyLys 131
 DB 2228 GAGCTGGAGGAGTACAACAAGATCTCTGTGGATATGGAACACCACTACAGCGTGGCCACT 2287
 QY 132 ValCysAsnProAspAsnProGlnGluCysLeuLeuGluProGlyLeuAsnGluLeu 151
 DB 2288 GTGTGCCACCCGAATGGC-----AGCTGCTGCACCTCGAGCCAGATCATCAACAGGCTGC 2341
 QY 152 MetAlaAsnSerLeuAspTyrAsnGluAtrLeuTyrAlaTyrGluSerTyrPargSerGlu 171
 DB 2342 ATGCCACATCCCGGAATATAGAGACCTTTATGGCATGGAGGCGTGGCGAGACAAG 2401
 QY 172 ValGlyLysGlnLeuArgProLeuTyrGluGluTyrValValLeuLysAsnGluMetAla 191
 DB 2402 GCGGGAGAGCCATCTCCACAGTTTATCCCGAAATAGTGGAACTCATCAACAGGCTGC 2461
 QY 192 ArgAlaAsnHisTyrGluAspTyrGlyAspTyrTyrArgGlyAspTyrGluValAsnGly 211
 DB 2462 CGGCTCAATGGCTATGTAGATGAGGGGACTCGTGAGGCTTATGTACGAGACACCATCC 2521
 QY 212 ValAspGlyTyrAspTyrSerArgGlyGlnLeuIleGluAspValGluHisThrPheGlu 231
 DB 2522 CTGGAG-----CAAGACCTGGAGCGGCTCTTCCAG 2551
 QY 232 GluIleLysProLeuTyrGluHisLeuHisAlaTyrValArgAlaLysLeuMetAsnAla 251
 DB 2552 GAGCTCAGCCACTTACCTCAACCTGCTGCTAGCTGCGCGCGCGCTGCACCGCTCAC 2611
 QY 252 Tyr---ProSerTyrIleSerProIleGlyCysLeuProAlaHisLeuLeuGlyAspMet 270
 DB 2612 TAGCGGGCCAGCACATCAACCTGGAGGGCCCATTTCTGCTCACCTGCTGGGGAAATG 2671
 QY 271 TrpGlyArgPheThrPheThrAsnLeuTyrSerLeuThrValProPheGlyGlnLysProAsn 290
 DB 2672 TGGGCGCAGACCTGGTCCCAACATCATGATGTGGTGTGCTCCCTTCCTTCAGCCCCCTCG 2731
 QY 291 IleAspValThrAspAlaMetValAspGlnAlaTyrAspAlaGlnArgIlePheLysGlu 310
 DB 2732 ATGGACACACAGAGCTATGTAAGACAGGCGTGGAGCCGCCAGGAGGAGTGTAAAGGAG 2791
 QY 311 AlaGluLysPhePheValSerValGlyLeuProAsnMetThrGlnGlyPheThrGluAsn 330
 DB 2792 GCTGATGATTCTTCACTCCCTGGGGCTGCTGCCCGCTCTCTCTGAGTGTGGAACAAG 2851
 QY 331 SerMetLeuThrAspProGlyAsnValGlnLysAlaValCysHisProThrAlaTyrAsp 350
 DB 2852 TCGATGCTGGAGAGCAACACCGGGGGAGGTTGCTGCGCACGCTCGGCCCTGGGAC 2911
 QY 351 LeuGlyLysGly---AspPheArgIleLeuMetCysThrLysValThrMetAspPhe 369

Db 2912 TTCTACAACGGCAAGGACTTCCGGATCAAGCAGTGCACCAACCGTGAACCTGGAGGACCTG 2971
 Qy 370 LeuThrAlaHisHisGluMetGlyHisIleGlnTyrAspMetAlaTyrAlaAlaGlnPro 389
 Db 2972 GTGGTGGCCCAACCAAGGACACATCCAGTATTTTCATGCAGTACAAGACTTACCT 3031
 Qy 390 PheLeuLeuArgAsnGlyAlaAsnGluGlyPheHisGluAlaValGlyGluIleMetSer 409
 Db 3032 GTGGCCTTGAGGGAGGTGCCAACCCGGCTTCCATGAGGCCATTGGGACGTGCTAGCC 3091
 Qy 410 LeuSerAlaAlaThrProLysHisHisLysSerIleGlyLeuLeuSerProAspPheGln 429
 Db 3092 CTCTCAGTGTCTAGCCCAACGACCTGCACAGTCTCAACCTGCTGAGCAGTGAAGGGTGGC 3151
 Qy 430 GluAspAsnGluThrGluIleAsnPheLeuLeuLysGlnAlaLeuThrIleValGlyThr 449
 Db 3152 AGCGAC---GAGCATGACATCAACTTCTGATGAGATGGCCCTTGACAAAGATCGCCTTT 3208
 Qy 450 LeuProPheThrTyrMetLeuGluLysTyrArgTrpMetValPheLysGlyGluIlePro 469
 Db 3209 ATCCCTTCAGTACCTCGTGCATCAGTGGCGCTGGAGGGTATTGATGGAAGCATCACC 3268
 Qy 470 LysAspGlnTrpMetLysLysTyrTrpGluMetLysArgGluIleValValGlu 489
 Db 3269 AAGGAGAACTATAACCAAGAGTGTGAGCCTCAGGCTGAAGTACCAGGGCCTCTGCCCC 3328
 Qy 490 ProValProHisAspGluThrTyrCysAspProAlaSerLeuPheHisValSerAsnAsp 509
 Db 3329 CCAGTGGCCAGGACTCAAGTGACTTTGACCCAGGGGCCAAGTCCACATCTCTCTAGC 3388
 Qy 510 TyrSerPheIleArgTyrTyrThrArgThrLeuTyrGlnPheGlnPheGlnGluAlaLeu 529
 Db 3389 GTGCCTTACATCAGGTACTTTGTGAGCTTCATCATCCAGTTCCAGTTCCACAGGGCACTG 3448
 Qy 530 CysGlnAlaAlaLysHisGluGlyProLeuHisLysCysAspIleSerAsnSerThrGlu 549
 Db 3449 TGCCAGGCAGTGGCCACACGGGCCCTGCACAAAGTGTGACATCTACCAGTCCCAAGGAG 3508
 Qy 550 AlaGlyGlnLysLeuPheAsnMetLeuArgLeuGlyLysSerGluProTrpThrLeuAla 569
 Db 3509 GCCGGGACGCCCTGGCCAGCCCATGAAGCTGGGCTTCAGTAGGCCGTGGCCGGAAGCC 3568
 Qy 570 LeuGluAsnValValGlyAlaLysAsnMetAsnValArgProLeuLeuAsnTyrPheGlu 589
 Db 3569 ATGCAGCTGATCACGGGCCAGCCCAACATGAGCGCCTGGGCCATGTTGAGCTACTTCAAG 3628
 Qy 590 ProLeuPheThrTrpLeuLysAspGlnAsnLys-----AsnSerPheValGlyTyr--- 606
 Db 3629 CCGCTGCTGGACTGGCTCCGACGAGGACGAGCTGCATGGGGACAGCTGGGCTGGCCG 3688
 Qy 607 SerThrAspTrpSerProTyrAlaAspGlnSer 617
 Db 3689 CAGTACAACGTGACGCCGAACCTCCGCTCGCTCA 3721

Search completed: October 9, 2002, 18:07:43
 Job time : 295 secs